YAP1 Activation by Human Papillomavirus E7 Promotes Basal Cell Identity in Squamous Epithelia

Joshua Hatterschide¹, Paola Castagnino¹, Hee Won Kim¹, Steven M. Sperry², Kathleen T. Montone³, Devraj Basu¹, Elizabeth A. White^{1*}

¹Department of Otorhinolaryngology: Head and Neck Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

²Current address: Department of Otolaryngology-Head and Neck Surgery, Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, U.S.A.

³Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

* Correspondence: Elizabeth A. White, eawhite@pennmedicine.upenn.edu

Abstract

Persistent human papillomavirus (HPV) infection of stratified squamous epithelial cells causes nearly five percent of cancer cases worldwide. HPV-positive oropharyngeal cancers harbor few mutations in the Hippo signaling pathway compared to HPV-negative cancers at the same anatomical site, prompting the hypothesis that an HPV-encoded protein inactivates the Hippo pathway and activates the Hippo effector YAP1. The HPV E7 oncoprotein is required for HPV infection and for HPV-mediated oncogenic transformation. We investigated the effects of HPV oncoproteins on YAP1 and found that E7 activates YAP1, promoting YAP1 nuclear localization in basal epithelial cells. YAP1 activation by HPV E7 required that E7 bind and degrade the tumor suppressor PTPN14. E7 required YAP1 transcriptional activity to extend the lifespan of primary keratinocytes, indicating that YAP1 activation contributes to E7 carcinogenic activity. Maintaining infection in basal cells is critical for HPV persistence, and here we demonstrate that YAP1 activation causes HPV E7 expressing cells to be retained in the basal compartment of stratified epithelia. We propose that YAP1 activation resulting from PTPN14 inactivation is an essential, targetable activity of the HPV E7 oncoprotein relevant to HPV infection and carcinogenesis.

Introduction

Human papillomaviruses (HPV) are non-enveloped viruses with circular double-stranded DNA genomes that infect keratinocytes in stratified squamous epithelia (Doorbar et al., 2015; Graham, 2017; McBride, 2017). Although most HPV infections are cleared by the immune system, some infections persist and form higher grade lesions that can lead to cancer (Koshiol et al., 2008; McBride, 2021; Radley et al., 2016; Rositch et al., 2013). HPV infection at mucosal epithelial sites causes cancers including oropharyngeal, cervical, vaginal, penile, and anal malignancies (de Martel et al., 2017; Gillison et al., 2015). Nearly 5% of human cancer cases are caused by persistent infection with one of the high-risk (oncogenic) human papillomavirus genotypes (de Martel et al., 2020).

Inactivation of host cell tumor suppressors by the high-risk HPV E6 and E7 oncoproteins modulates cellular processes that enable HPV persistence. Two well-characterized instances of tumor suppressor inactivation by HPV are high-risk HPV E6 proteins targeting p53 for proteasome-mediated degradation and high-risk HPV E7 proteins binding and degrading the retinoblastoma protein (RB1) (Heck et al., 1992; Münger et al., 1989; Scheffner et al., 1990; Seavey et al., 1999; Werness et al., 1990). Both p53 degradation and RB1 inactivation are required for productive HPV infection (Collins et al., 2005; Flores et al., 2000; Kho et al., 2013; McLaughlin-Drubin et al., 2005; Wang et al., 2009). In addition to supporting productive infection, E7 is essential for HPV-mediated carcinogenesis (Mirabello et al., 2017). The impact of the HPV oncoproteins on cell growth control pathways is reflected in human cancer genomic data: genes in the p53 pathway and in the RB1-related cell cycle pathway are frequently mutated in HPV-negative head and neck squamous cell carcinoma (HNSCC) but infrequently mutated in HPV-positive HNSCC (Sanchez-Vega et al., 2018).

Although some of the growth-promoting activities of high-risk HPV E6 and E7 are well established, open questions remain. RB1 binding/degradation by high-risk HPV E7 is necessary but insufficient for E7 transforming activity (Balsitis et al., 2006, 2005; Banks et al., 1990; Ciccolini

et al., 1994; Helt and Galloway, 2002; Huh et al., 2005; Ibaraki et al., 1993; Jewers et al., 1992; Phelps et al., 1992; Strati and Lambert, 2007; White et al., 2015). Papillomavirus researchers have sought to identify one or more activities of HPV E7 that cooperate with RB1 inactivation to promote carcinogenesis and to identify the cellular pathway affected by such an activity. Human cancer genomic data indicates that like the p53 and cell cycle pathways, the Hippo signaling pathway is more frequently mutated in HPV-negative than in HPV-positive HNSCC. The core Hippo pathway consists of a kinase cascade upstream of the effector proteins Yes-Associated Protein (YAP1) and its paralogue TAZ. When the Hippo kinases are inactive, YAP1 and TAZ are activated and translocate to the nucleus. In stratified squamous epithelia YAP1 is primarily expressed in the basal layer, where YAP1 activation is regulated by contextual cues including cell density, tension in the extracellular matrix, and contact with the basement membrane (Elbediwy et al., 2016; Totaro et al., 2017; Zhang et al., 2011). In normal stratified squamous epithelia, activation of YAP1 and TAZ promotes expansion of the basal cell compartment, and inhibition of YAP1 and TAZ allows keratinocytes to differentiate (Beverdam et al., 2013; Elbediwy and Thompson, 2018; Schlegelmilch et al., 2011; Totaro et al., 2017; Yuan et al., 2020; Zhang et al., 2011). Mutations in many of the tumor suppressors upstream of YAP1/TAZ are common in a variety of cancer types (Moroishi et al., 2015).

Non-receptor protein tyrosine phosphatase 14 (PTPN14) has been implicated as a tumor suppressor and negative regulator of YAP1 (Knight et al., 2018; Mello et al., 2017; Poernbacher et al., 2012; Wang et al., 2012). Diverse HPV E7 bind directly to PTPN14 and recruit the E3 ligase UBR4 to direct PTPN14 for proteasome-mediated degradation (Szalmás et al., 2017; White et al., 2016, 2012b; Yun et al., 2019). We have shown that PTPN14 degradation and RB1 binding/degradation are separable activities of HPV E7 that each contribute to E7 carcinogenic activity (Hatterschide et al., 2020, 2019; White et al., 2016). However, the downstream consequences of PTPN14 degradation are poorly understood, and so far we have not observed

that PTPN14 inactivation in human keratinocytes causes an increase in canonical YAP1 target genes *CTGF* and *CYR61*.

These observations regarding an additional transforming activity of HPV E7, the ability of E7 to inactivate PTPN14, and the relative paucity of mutations in the Hippo pathway in HPV-positive HNSCC led us to hypothesize that HPV E7-mediated activation of YAP1 is required for the transforming activity of high-risk HPV E7. Here we show that expression of high-risk HPV E7 is sufficient to activate YAP1 and that HPV E7 requires YAP1/TAZ-TEAD transcriptional activity to promote cell growth. We demonstrate that HPV E7 must bind PTPN14 to activate YAP1 and that PTPN14 inactivation alone is sufficient to activate YAP1. YAP1 activation by HPV E7 is restricted to the basal layer of the epithelium where we found *PTPN14* expression to be enriched.

Our finding that either HPV E7 or PTPN14 loss activate YAP1 specifically in basal epithelial cells led us to investigate the role of YAP1 activation during normal HPV infection. HPV infection begins in basal epithelial keratinocytes (Day and Schelhaas, 2014; Pyeon et al., 2009; Roberts et al., 2007) and infected basal cells are the site of persistent HPV infection. The basal cell compartment contains the only long-lived cells in the epithelium and the HPV genome can be maintained in dividing basal cells without productive replication (Egawa et al., 2012; Parish et al., 2006; You et al., 2004). Activation of YAP1 and TAZ has been proposed to maintain the progenitor cell state in several different epithelia (Beverdam et al., 2013; Heng et al., 2020; Hicks-Berthet et al., 2021; Szymaniak et al., 2015; Yimlamai et al., 2014; Zhao et al., 2014). If YAP1 activation by E7 promotes the maintenance of a basal cell state in stratified squamous epithelia, YAP1 activation could facilitate the persistence of HPV-positive cells. Testing this hypothesis, we found that YAP1 activation and PTPN14 degradation by E7 both promote the maintenance of cells in the basal compartment of stratified epithelia. We propose that YAP1 activation facilitates HPV persistence and contributes to the carcinogenic activity of high-risk HPV E7.

Results

HPV E7 activates YAP1 in basal keratinocytes

A comprehensive analysis of somatic mutations and copy number variations in human tumor samples revealed that the cell cycle, p53, and Hippo pathways are the three pathways that exhibit the greatest difference in alteration frequency in HPV-negative vs HPV-positive HNSCC (Sanchez-Vega et al., 2018). We used data made available by The Cancer Genome Atlas (TCGA) through cBioPortal (Lawrence et al., 2015) to recapitulate the finding that genes in these pathways are altered at a lower frequency in HPV-positive than in HPV-negative HNSCC (Figure 1A and Figure 1—figure supplement 1). However, most HPV-positive HNSCC arise in the oropharynx. We repeated the analysis of pathway alteration rates using data only from HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas (OPSCC) (Figure 1A and Figure 1—figure supplement 1). Consistent with previous findings, HPV-negative OPSCC were more frequently altered in the p53, cell cycle, and Hippo pathways than HPV-positive OPSCC. Many of the Hippo pathway alterations in HPV-negative HNSCC or OPSCC are amplification of the YAP1/TAZ oncogenes or inactivating mutation in an upstream inhibitor of YAP1/TAZ. Either alteration type is consistent with a carcinogenic role for YAP1 activation in HNSCC.

To test whether an HPV-encoded protein activates YAP1, we grew three dimensional (3D) organotypic epithelial cultures to model the differentiation of keratinocytes into basal and suprabasal compartments. Organotypic cultures of primary human foreskin keratinocytes (HFK) harboring an HPV18 genome exhibited increased YAP1 staining and increased YAP1 nuclear localization, indicative of YAP1 activation, particularly in the basal layer of the epithelium, compared to HFK cultures (Figure 1B and Figure 1—figure supplement 2A,B). Proliferating cell nuclear antigen (PCNA) transcription increases upon RB1 inactivation and is a marker of HPV E7 expression. In contrast to the basal layer-specific compartmentalization of YAP1 activation in the HPV18 genome containing cells, PCNA levels were increased in these cultures in both the basal and suprabasal layers of the epithelium.

Figure 1 | HPV E7 activates YAP1 in basal epithelial keratinocytes. (A) cBioPortal analysis for total genomic mutations and copy number alterations in HPV+/- OPSCC and HNSCC. Graph displays the percent of tumors with alterations in each pathway. Statistical significance was determined by Fisher's exact test. (B-D) Organotypic cultures were grown from primary HFK, HFK harboring the HPV18 genome, or HFK transduced with retroviral expression encoding HPV E6 or E7 proteins. FFPE sections of cultures grown from (C) HFK or HFK harboring the HPV18 genome, (D) HFK or HFK expressing HPV16 E7 or HPV18 E7, or (E) HFK or HFK expressing HPV16 E6 or HPV16 E7 were stained for YAP1 (magenta), PCNA (green), and Hoechst (gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μ m. Inset scale bars = 25 μ m.

We next tested whether high-risk HPV E6 or E7 alone was sufficient to activate YAP1. HFK transduced with retroviral expression vectors encoding HPV16 E6, HPV16 E7, or HPV18 E7 were used to grow organotypic cultures. YAP1 expression and nuclear localization were increased in the HPV16 E7 and HPV18 E7 expressing cells relative to parental HFK cells (Figure 1C and Figure 1—figure supplement 3A-C). As in the HPV18 genome-containing cells, YAP1 activation was restricted to the basal epithelial layer. YAP1 expression or nuclear localization did not increase in organotypic cultures of HPV16 E6 expressing cells (Figure 1D and Figure 1—figure supplement 4). Constitutive expression of either HPV16 E7 or HPV18 E7 induced PCNA expression in basal and suprabasal cells. We conclude that HPV promotes increased YAP1 expression and nuclear localization in basal keratinocytes and that E7 is sufficient for YAP1 activation.

HPV E7 activates YAP1 in keratinocytes through PTPN14 degradation

We previously discovered that HPV E7 targets the YAP1 inhibitor PTPN14 for proteasome-mediated degradation (White et al., 2016, 2012b). We tested whether loss of PTPN14 expression in keratinocytes was sufficient to activate YAP1 in stratified epithelia by growing 3D organotypic cultures from previously described control and PTPN14 knockout (KO) N/Tert-Cas9 keratinocytes (Hatterschide et al., 2019). We found that YAP1 levels and YAP1 nuclear localization were increased in PTPN14 KO cultures compared to controls (Figure 2A and Figure 2—figure supplement 1A-C). YAP1 activation in basal epithelial cells lacking PTPN14 was comparable to YAP1 activation in HPV E7 cells. We conclude that loss of PTPN14 expression activates YAP1 in basal keratinocytes.

A highly conserved C-terminal arginine in E7 makes a direct interaction with the C-terminus of PTPN14, and the HPV18 E7 R84S variant is unable to bind or degrade PTPN14 (Hatterschide et al., 2020; Yun et al., 2019). To test whether PTPN14 degradation by HPV E7 is required for activation of YAP1, we grew 3D organotypic cultures using primary HFK transduced

Figure 2 | HPV E7 activates YAP1 in basal keratinocytes through PTPN14 degradation. Organotypic cultures were grown from N/Tert-Cas9 keratinocytes or primary HFK transduced with retroviral expression vectors encoding HPV18 E7 WT or R84S. (A) FFPE sections of cultures grown from mock or sgPTPN14 transfected N/Tert-Cas9 keratinocytes were stained for YAP1 (magenta), IVL (green), and Hoechst (Gray). (B) FFPE sections of cultures grown from parental HFK, HPV18 E7 WT or HPV18 E7 R84S expressing HFK were stained for YAP1 (magenta), PCNA (green), and Hoechst (Gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μm. Inset scale bars = 25 μm. (C-F) Quantification of the number of (C and E) basal cells and (D and F) suprabasal cells per 100 μm of epidermis. Graphs display the mean ± SD and each individual data point (independent cultures). Statistical significance was determined by ANOVA (*p<0.05, ***p<0.001).

with retroviral expression vectors encoding HPV18 E7 wild type (WT) or HPV18 E7 R84S. Indeed, YAP1 expression and nuclear localization in the basal layer of HPV18 E7 R84S cultures were reduced compared to HPV18 E7 WT controls (Figure 2B and Figure 2—figure supplement 2).

In addition to activating YAP1, PTPN14 loss increased basal cell density from an average of 5.5 cells per 100 μm in control cultures to 9.0 cells per 100 μm in PTPN14 KO cultures (Figure 2C). Basal cell density was higher in HPV18 E7 WT cultures (9.4 cells per 100 μm) than in HPV18 E7 R84S cultures (to 7.1 cells per 100 μm) (Figure 2E). No statistically significant difference in suprabasal cell density was observed in either comparison (Figure 2D,F). We conclude that E7 expression or PTPN14 loss in stratified squamous epithelia is sufficient to activate YAP1 in the basal layer of the epithelium and increase basal cell density.

PTPN14 expression is enriched in basal keratinocytes

YAP1 activation was restricted to basal epithelial cells in our organotypic cultures leading us to hypothesize that PTPN14 may act as a basal layer specific inhibitor of YAP1. We therefore sought to determine whether *PTPN14* expression is restricted to a specific subset of cells in the stratified epithelium. In a recent single cell-RNA seq analysis of human neonatal foreskin epidermis, *PTPN14* mRNA expression was enriched in the basal-III cluster, a subset of basal cells predicted to differentiate directly into spinous cells (Figure 3A,B) (S. Wang et al., 2020). *PTPN14* expression was higher in basal-III cells than in the spinous or granular cell clusters. To test whether *PTPN14* expression is higher in basal or suprabasal cells in our cultures, we used laser capture microdissection to isolate basal and suprabasal layers from 3D organotypic cultures grown from unmodified primary HFK (Figure 3C). We found that there was a ~5-fold enrichment of *PTPN14* mRNA in the basal epithelial layer compared to the suprabasal layers (Figure 3D). As expected, the basal integrins *ITGA6* and *ITGB4* were expressed in the basal layer (Figure 3E) and the differentiation markers *KRT1* and *IVL* were expressed in the suprabasal layers (Figure 3F). The same pattern of *PTPN14* mRNA expression was observed in an organotypic culture grown from

Figure 3 | PTPN14 expression is enriched in basal keratinocytes. (A-B) Single-cell RNA sequencing data and clustering analysis from Wang et al. was reanalyzed to assess PTPN14 expression in different subsets of epidermal cells. (A) Diagram of epidermis; shading depicts tissue localization of cell clusters. (B) For each donor, the mean of PTPN14 mRNA expression was calculated for each cell cluster. Graphs display the mean of PTPN14 mRNA expression for each donor (circles) as well as the mean of all five donors $\pm$ SEM (bars and error bars). Statistical significance was determined by ANOVA (* $p < 0.05$, ** $p < 0.01$). (C-F) Basal and suprabasal layers from organotypic cultures were dissected using laser capture microdissection. (C) Representative images of HFK cultures before and after individual laser dissections. Hundreds of such cuts were performed per sample. (D-F) RNA was purified from isolated layers and qRT-PCR was used to assess the expression of PTPN14 (D), basal cell markers ITGA6 and ITGB4 (E), and differentiation markers KRT1 and IVL (F). Graphs display the mean and each individual data point.

primary HFK expressing HPV18 E7 WT (Figure 3—figure supplement 1A-C). We conclude that *PTPN14* mRNA is enriched in basal keratinocytes in the presence or absence of HPV E7. Our data support that *PTPN14* acts as a YAP1 inhibitor specifically in the basal compartment of stratified epithelia.

YAP1/TAZ regulate differentiation downstream of *PTPN14*

In previous unbiased experiments we found that the primary effect of *PTPN14* inactivation on transcription is to repress epithelial differentiation gene expression (Hatterschide et al., 2020, 2019). However, we also observed that *PTPN14* inactivation did not increase expression of the canonical YAP1/TAZ targets *CTGF* and *CYR61*. Consistent with this difference there was minimal overlap between *PTPN14*-dependent differentially expressed genes and the genes listed in the MSigDB conserved YAP1 signature (Figure 4A). We therefore asked whether the ability of *PTPN14* to regulate differentiation gene expression requires YAP1/TAZ as intermediates. Transduction of keratinocytes with a *PTPN14* lentivirus induced the expression of the differentiation markers *KRT10* and *IVL* in a dose-dependent manner (Figure 4—figure supplement 1A-C). To test whether *PTPN14* required YAP1/TAZ to increase *KRT1* and *IVL*, we transfected HFK with siRNAs targeting *YAP1* and *WWTR1* then transduced the cells with *PTPN14* lentivirus (Figure 4B). HFK transfected with control siRNA exhibited the expected increase in *KRT1* and *IVL* after transduction with *PTPN14* lentivirus (Figure 4C,D and Figure 4—figure supplement 2A,B). However, keratinocytes depleted of YAP1/TAZ did not express relatively more *KRT1* or *IVL* when *PTPN14* was overexpressed than when it was not. We conclude that *PTPN14* requires YAP1 and/or TAZ to regulate differentiation gene expression in keratinocytes. Both pairs of YAP1/TAZ siRNA had the same effect on differentiation in response to *PTPN14* overexpression yet only one pair efficiently depleted TAZ protein levels (Figure 4B), leading us to speculate that YAP1 is the key intermediate connecting *PTPN14* levels to differentiation gene expression.

Figure 4 | YAP1/TAZ regulate differentiation downstream of PTPN14. (A) Venn diagram comparing the MSigDB YAP conserved signature to the differentially expressed genes (DEG) from our two published experiments that reflect PTPN14 loss in keratinocytes. (B-D) YAP1 and WWTR1 were simultaneously knocked down by siRNA transfection in HFK. Transfected HFK were then transduced with PTPN14 lentivirus at 24h post transfection. Cells were lysed for protein and total cellular RNA at 72h post transfection. (B) Cell lysates were subjected to SDS/PAGE/Western analysis and probed with antibodies to PTPN14, YAP1, TAZ, and Actin. (C and D) qRT-PCR was used to measure the expression of the differentiation markers KRT1 and IVL relative to G6PD. Graphs display fold change in gene expression relative to the mock transduced cells. (E-I) Primary HFK were transfected with siRNAs targeting YAP1, WWTR1 (TAZ), PTPN14, LATS1, and LATS2. Two siRNAs were used per target. qRT-PCR was used to measure gene expression for: the differentiation markers IVL (E) and KRT1 (F), and the canonical YAP1/TAZ targets CTGF (G) and CYR61 (H). Data confirming that individual siRNA transfections depleted intended transcripts is summarized in a heatmap of log₂(fold-change) levels (I). Bar graphs display the mean $\pm$ SD of three independent replicates. Statistical significance was determined by ANOVA (* p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001).

Next, we tested whether repression of keratinocyte differentiation occurs upon loss of LATS1 and LATS2, the core Hippo pathway kinases that phosphorylate and inhibit YAP1 and TAZ. We used siRNAs to deplete *PTPN14*, *LATS1*, or *LATS2* and measured the expression of the differentiation markers *KRT1* and *IVL* (Figure 4E,F). Depletion of *PTPN14*, *LATS1*, or *LATS2* all decreased differentiation gene expression to a similar degree. Consistent with our previous experiments, none of the three knockdowns significantly affected the levels of *CTGF* or *CYR61* (Figure 4G-H). Direct depletion of *YAP1* or *WWTR1* affected both differentiation gene expression and *CTGF/CYR61* levels. *YAP1* knockdown always had a stronger effect than did *WWTR1* knockdown and our qRT-PCR analyses supported that *WWTR1* transcript levels were low in HFK. This result shows that inactivation of three different YAP1 inhibitors dampens differentiation gene expression and does not increase canonical YAP1 target gene expression in keratinocytes. Taken together, these data support that PTPN14 promotes differentiation through inhibition of YAP1/TAZ despite not affecting canonical YAP1/TAZ target genes.

HPV-positive HNSCC are less differentiated than HPV-negative HNSCC

We next asked whether the gene expression pattern observed downstream of PTPN14 loss is reflected in HPV-positive cancers. HPV-positive HNSCC have a strong propensity toward poorly differentiated, basaloid histology (Mendelsohn et al., 2010; Pai and Westra, 2009), which is reflected in their transcriptional profile (Hatterschide et al., 2019). We confirmed the relationship between HPV positivity and greater impairment of differentiation by immunohistochemical analysis of the differentiation marker KRT1 in sections of 14 HPV-negative tumors and 48 HPV-positive tumors (Figure 5A). 43% of HPV-negative tumors and 12.5% of HPV-positive tumors stained positive for KRT1. We additionally measured gene expression in patient-derived xenograft (PDX) models generated from human HNSCC. We measured *KRT1*, *KRT10*, and *IVL* levels using RNA extracted from 11 HPV-negative and 8 HPV-positive HNSCC PDX. Each differentiation marker was expressed at a markedly lower level in HPV-positive PDX than in HPV-negative PDX

Figure 5 | HPV-positive HNSCC are less differentiated than HPV-negative HNSCC. (A) Human HNSCC tumor samples were stained for KRT1 (left). Scale bar = 100 μ m. Graph displays the percentage of tumors that were KRT1⁺ (right). Statistical significance was determined by Fisher's exact test. (B-C) Total RNA was purified from PDX samples and qRT-PCR was used to assess gene expression of (B) the differentiation markers KRT1, KRT10, and IVL and (C) the canonical YAP1/TAZ targets CTGF and CYR61. Statistical significance was determined by Mann-Whitney nonparametric test. (* $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$).

(Figure 5B). We observed the same pattern of differentiation marker gene expression in an analysis of transcriptomic data from other cohorts (Figure 5—figure supplement 1A-C) (Lawrence et al., 2015). Having confirmed that HPV-positive HNSCC exhibit reduced expression of differentiation markers than do HPV-negative HNSCC, we measured *CTGF* and *CYR61* levels. We found no significant difference in expression of these canonical YAP1/TAZ target genes in HPV-positive vs HPV-negative PDX, although there was a trend towards higher *CTGF* in the HPV-positive PDX (Figure 5C and Figure 5—figure supplement 1D,E). The pattern of low expression of differentiation markers and unchanged canonical YAP1/TAZ target gene expression in HPV-positive versus HPV-negative patient samples is consistent with the effects of PTPN14 inactivation in cultured cells.

High-risk HPV E7 require YAP1/TAZ-TEAD transcriptional activity to extend the lifespan of primary keratinocytes.

High-risk but not low-risk HPV E7 proteins can extend the lifespan of primary keratinocytes (Halbert et al., 1991). The TEADi protein is a genetically encoded competitive inhibitor that prevents binding between YAP1/TAZ and TEAD transcription factors (Yuan et al., 2020). We used TEADi to test whether YAP1/TAZ-TEAD transcriptional activity was required for high-risk HPV E7 to extend the lifespan of primary HFK. We transduced HFK with retroviral vectors encoding GFP, HPV16 E7, or HPV18 E7 plus a lentiviral vector encoding doxycycline-inducible GFP-TEADi. As anticipated, HPV16 E7 or HPV18 E7 extended the lifespan of primary HFK based on cumulative population doublings (Figures 6A,B). TEADi induction upon doxycycline treatment decreased the lifespan of primary HFK in the presence or absence of E7, but the effect of YAP1/TAZ-TEAD inhibition was greater in the HPV16 E7 and HPV18 E7 cells, where E7 had minimal ability to promote growth in the presence of TEADi. We conclude that high-risk HPV E7 proteins require YAP1/TAZ-TEAD transcriptional activity for their lifespan extending capacity in primary keratinocytes.

Figure 6 | High-risk HPV E7 requires YAP1/TAZ-TEAD transcriptional activity to extend the lifespan of primary keratinocytes. Primary HFK were transduced with retroviruses encoding HPV16 E7, HPV18 E7, or GFP, plus pInducer20 TEADi lentivirus. Each cell population was cultured with or without 1 μ g/mL doxycycline in the media for 38 days and population doublings were tracked with each passage. Graph displays the mean $\pm$ SD of two independently transduced cell populations per condition.

PTPN14 loss and YAP1 activation promote basal cell retention in organotypic cultures

YAP1 overexpression impairs differentiation and promotes progenitor cell identity in squamous and non-squamous epithelia. HPV infection is maintained in a reservoir of infected basal cells and productive virus replication begins upon commitment to differentiation. To better understand how repression of differentiation downstream of YAP1 activation affects HPV viral biology, we developed an assay to measure cell retention in the basal epithelial layer. We hypothesized that YAP1 activation by HPV E7 might promote the adoption of a basal cell identity in stratified squamous epithelia. In our cell fate monitoring assay, a small proportion of GFP-labeled cells were mixed with unmodified, parental HFK, and the pool was used to generate organotypic cultures in which normal labeled cells are randomly distributed throughout the epithelium.

Our initial experiment tested whether YAP1 activation altered cell fate in stratified squamous epithelia. We used GFP-labeled tracing cells that expressed doxycycline-inducible YAP1 WT, YAP1 S127A (hyperactive), or YAP1 S94A (cannot bind TEAD transcription factors) (Figure 7—figure supplement 1A,B). In organotypic cultures grown from a 1:25 mixture of GFP-labeled cells and unmodified HFK, about 20% of uninduced GFP+ cells were found in the basal layer. Induction of YAP1 WT or YAP1 S127A expression was sufficient to promote the retention of nearly 60% of labeled cells in the basal layer of the epithelium (Figure 7A,B). Only around 40% of GFP+ cells were found in the basal layer when YAP1 S94A was induced. These data indicate that YAP1 activation causes cells to be retained in the basal layer of a stratified squamous epithelium. The ability of YAP1 to bind TEAD transcription factors contributed to its activity in the cell fate assay.

We next tested whether loss of PTPN14 expression was sufficient to promote basal cell identity. We grew organotypic cultures from mixtures of unmodified primary HFK and GFP-labeled control or PTPN14 KO HFK (Figure 7—figure supplement 1C,D). 60-70% of PTPN14 KO tracer cells were found in the basal layer when either of two PTPN14 guide RNAs were used whereas

Figure 7 | PTPN14 loss and YAP1 activation by HPV E7 promote basal cell retention in organotypic cultures. Organotypic cultures were grown from GFP-labeled HFK mixed with unmodified HFK. (A-B) GFP-labeled HFK were transduced with lentiviral vectors encoding YAP1 WT, YAP1 S127A, or YAP1 S94A under the control of a doxycycline inducible promoter. GFP-labeled YAP1 cells were mixed 1:25 into unmodified HFK and organotypic cultures were grown from the mixture. Cultures were grown +/- 1 μ g/mL doxycycline. (C-D) GFP-labeled HFK were transduced with LentiCRISPR v2 vectors encoding control or PTPN14 targeting sgRNAs. GFP-labeled cells were mixed 1:25 into unmodified HFK and organotypic cultures were grown from the mixture. (E-F) GFP-labeled HFK were transduced with HPV18 E7 WT, HPV18 E7 R84S, or the empty vector (EV). GFP-labeled HPV18 E7 cells were mixed 1:50 into unmodified HFK and organotypic cultures were grown from the mixture. (A, C, E) FFPE sections of cultures were stained for GFP (green), IVL (grey), and Hoechst (blue). Scale bar = 100 μ m. (B, D, F) Quantification of the percentage of GFP+ cells found in the basal layer. Graphs display the mean $\pm$ SD and each individual data point (independent cultures). Shapes indicate cultures grown from different HFK donors. Statistical significance was determined by ANOVA. (* p <0.05, ** p <0.01).

about 20% of control tracer cells were retained in the basal layer (Figure 7C,D). Thus, PTPN14 knockout is sufficient to promote basal cell fate determination in keratinocytes.

Next, we tested whether HPV E7 promoted basal cell retention and if so, whether its cell retention activity required PTPN14 degradation. We grew organotypic cultures from mixtures of GFP-labeled HFK expressing HPV18 E7 WT, HPV18 E7 R84S, or the empty vector control diluted 1:50 into unmodified primary HFK (Figure 7—figure supplement 1E,F). We found that nearly 80% of GFP-labeled HPV18 E7 WT tracer cells were retained in the basal layer compared to about 10% of labeled control cells (Figure 7E,F). HPV18 E7 WT labeled cells were numerous and grouped in clusters in the basal layer, suggesting that E7 promoted the clonal expansion of labeled basal cells. Both effects were dampened in experiments using HPV18 E7 R84S tracer cells (cannot degrade PTPN14). Labeled HPV18 E7 R84S cells exhibited varying degrees of basal cell expansion and basal cell retention and approximately 60% of labeled cells were in the basal layer. HPV18 E7 R84S retains the ability to inactivate RB1 and we interpret these data to mean that the proliferation of labeled basal cells resulted from RB1 inactivation. Finally, HPV18 E7 Δ DLLC cannot bind RB1 but can bind and degrade PTPN14. In a cell fate experiment using GFP-labeled HPV18 E7 Δ DLLC tracer cells, the labeled cells were present mainly as single cells in the basal layer (Figure 7—figure supplement 2A-B). The behavior of the two mutant HPV E7 proteins supports that PTPN14 degradation is required for basal cell retention and RB1 inactivation is required for basal cell expansion. We conclude that PTPN14 degradation and YAP1 activation by HPV18 E7 promote basal cell retention.

Discussion

YAP1 and TAZ are oncogenes that promote growth and inhibit differentiation in stratified squamous epithelia (Elbediwy et al., 2016; Schlegelmilch et al., 2011; Totaro et al., 2017; Yuan et al., 2020; Zhang et al., 2011). Here we report that HPV E7 activates YAP1 (Figure 1). YAP1/TAZ-TEAD transcriptional activity is required for the carcinogenic activity of HPV E7 (Figure

6) and YAP1 activation by E7 biases HPV E7-expressing cells to be retained in the basal epithelial layer (Figure 7). Based on these findings we propose that YAP1 activation by HPV E7 enables HPV-infected cells to persist in stratified epithelia. There is substantial evidence that RB1 inactivation is necessary but insufficient for the transforming activity of high-risk HPV E7 (Balsitis et al., 2006, 2005; Banks et al., 1990; Ciccolini et al., 1994; Helt and Galloway, 2002; Huh et al., 2005; Ibaraki et al., 1993; Jewers et al., 1992; Phelps et al., 1992; Strati and Lambert, 2007; White et al., 2015). We propose that YAP1 activation cooperates with RB1 inactivation to enable the transforming activity of HPV E7.

PTPN14 binding by HPV18 E7 was required for activation of YAP1 in the basal layer and PTPN14 KO was sufficient for the same effect (Figure 2). Highly conserved amino acids in E7 participate in binding to PTPN14 (Hatterschide et al., 2020; Yun et al., 2019), indicating that YAP1 activation and maintenance of basal cell state is likely shared among diverse papillomavirus E7 proteins. Some minor genotype-specific differences were apparent. HPV18 E7 depletes PTPN14 protein levels more efficiently than HPV16 E7 (Hatterschide et al., 2020; White et al., 2016), which is consistent with the observed stronger effect of HPV18 E7 on YAP1 nuclear localization in basal cells (Figure 1). Genotype-specific differences could also explain the stronger effect of TEADi on HPV18 E7 in lifespan extension assays (Figure 6). Although other reports have suggested that HPV might activate YAP1 (He et al., 2015; Morgan et al., 2020; Olmedo-Nieva et al., 2020; Webb Strickland et al., 2018), no specific activity of an HPV protein has previously been shown to enable YAP1 activation. Other groups have proposed that HPV E6 activates YAP1 (He et al., 2015; Webb Strickland et al., 2018), but we did not observe YAP1 activation by HPV E6. We conclude that activation of YAP1 by HPV E7 is contingent upon its ability to bind and degrade PTPN14.

Even when HPV E7 was expressed in all layers of a stratified epithelium, YAP1 levels and nuclear localization increased only in basal epithelial cells. We found that E7 required PTPN14 degradation to activate YAP1 and that PTPN14 was expressed predominantly in basal keratinocytes (Figure 3). Basal cell-specific expression of *PTPN14* is consistent with the

observation that it is regulated by p63, the master regulator of basal cell identity in stratified epithelia (Perez et al., 2007). We propose that PTPN14 inhibits YAP1 primarily in basal cells and that unlike the effects of E7 on RB1 in both differentiated and undifferentiated cells, E7 activates YAP1 primarily in basal cells.

Degradation of PTPN14 by HPV E7 represses keratinocyte differentiation but does not induce canonical Hippo pathway target genes (Hatterschide et al., 2020, 2019). Nonetheless, we found that PTPN14 overexpression promoted differentiation only in the presence of YAP1/TAZ (Figure 4C,D). Few studies have tested how YAP1 inhibitor inactivation alters gene expression downstream of YAP1. Here we demonstrate that inactivation of LATS1 or LATS2, two well-characterized inhibitors of YAP1/TAZ, also repressed differentiation genes but did not induce canonical YAP1/TAZ targets (Figure 4E-I). Taken together, these experiments indicate that PTPN14 acts through YAP1/TAZ to regulate differentiation in keratinocytes. It is so far unclear why *CTGF* and *CYR61* expression is sensitive to large changes in total levels of YAP1 or TAZ yet is unaffected by alterations in regulators upstream of YAP1/TAZ. Nonetheless, the pattern of low differentiation gene expression and unchanged expression of canonical YAP1/TAZ target genes caused by PTPN14 loss is consistent with gene expression differences between HPV-positive and HPV-negative HNSCC.

PTPN14 knockout and knockdown reduced differentiation gene expression in monolayer culture. Even so, we did not observe reduced differentiation in suprabasal layers of organotypic cultures grown from PTPN14 knockout cells (Figure 2A and Figure 2—figure supplement 1A-C). Using our cell fate monitoring assay, we determined that instead, HPV18 E7 promotes basal cell retention and that either YAP1 overexpression or PTPN14 KO are sufficient for this activity (Figure 7). The effect of YAP1 activation on cell fate in our assay resembles several experiments in which YAP1 promotes progenitor cell identity in airway and liver epithelia (Yimlamai et al., 2014; Zhao et al., 2014). Our findings demonstrate that YAP1 activation enables basal cell fate determination in stratified squamous epithelia and show that loss of an inhibitor of YAP1 has the same effect.

We conclude that one consequence of YAP1 activation by HPV E7 is that E7-expressing cells are retained in the basal layer of stratified squamous epithelia.

Although persistent infection is a prerequisite for HPV-mediated carcinogenesis, the mechanisms used by papillomaviruses to establish persistent infections remain incompletely understood. Maintaining infection in the basal cell compartment is critical for papillomavirus persistence. Substantial effort has been devoted to the mechanistic understanding of how the papillomavirus genome is stably maintained in the basal layer upon cell division. However, much less is known about how papillomaviruses manipulate epithelial cell fate to establish and expand the pool of infected basal cells. Previously, HPV E7 was believed to be primarily required to establish a cellular environment conducive to HPV DNA replication in suprabasal cells. We propose that a so far unappreciated role of E7 is that it activates YAP1 to facilitate HPV persistence by biasing infected cells to remain in the basal layer of the epithelium. Not every HPV E7-expressing cell was retained in the basal layer, so we do not anticipate that YAP1 activation would block differentiation-dependent HPV replication. HPV E6 also represses differentiation gene expression in keratinocytes and has been proposed to promote basal cell retention (Kranjec et al., 2017). Further research is needed to determine the extent to which different HPV genotypes depend on the activities of E6 or E7 for basal cell retention activity.

To the best of our knowledge, no other viruses are recognized to modulate cell fate decisions in solid tissues in a way that facilitates persistence. Some herpesviruses impact the choice between progenitor/differentiated cell fates in infected immune cells, for example Epstein-Barr Virus (EBV) restricts B-cell differentiation to facilitate viral latency (Knox and Carrigan, 1992; Niiya et al., 2006; Onnis et al., 2012; Romeo et al., 2019; Styles et al., 2017). Herpesviruses, polyomaviruses, and hepadnaviruses encode proteins proposed to activate YAP1/TAZ or alter Hippo signaling (Hwang et al., 2014; Liu et al., 2014, 2015; Nguyen et al., 2014; Shanzer et al., 2015; Tian et al., 2004; Z. Wang et al., 2020). Not all of the mechanisms used by these viruses to activate YAP1 nor the downstream consequences of YAP1 activation have been well defined.

Our finding that HPV E7 activates YAP1 to manipulate cell fate opens up an exciting new line of inquiry into how YAP1, TAZ, and the Hippo signaling pathway could impact viral infections by regulating tissue developmental processes.

YAP1 activation and PTPN14 are relevant to both viral and non-viral cancers. We found that a genetically encoded inhibitor of YAP1/TAZ-TEAD transcription inhibited the growth of high-risk HPV E7 expressing cells (Figure 6), indicating that high-risk HPV E7 proteins require YAP1 or TAZ for carcinogenesis. YAP1/TAZ activation is sufficient to drive carcinogenesis in mouse models of cervical and oral cancer (He et al., 2019; Nishio et al., 2020; Omori et al., 2020), and the YAP1 inhibitor verteporfin reduced the growth of HPV-positive tumors in a xenograft model (Liu et al., 2019). YAP1 activation correlates with the clinical stage of HPV infection (Nishio et al., 2020), and YAP1 localizes to the nucleus in HPV-positive cancers (Alzahrani et al., 2017). Basal cell carcinoma (BCC) is the non-viral cancer that is most clearly linked to PTPN14. Germline inactivating mutations in *PTPN14* are associated with a 4- to 8-fold increase in risk of BCC by age 70 (Olafsdottir et al., 2021) and somatic mutations in *PTPN14* are frequent in BCC (Bonilla et al., 2016). YAP1/TAZ-TEAD transcriptional activity also restricts differentiation in BCC cells (Yuan et al., 2021). We propose that the specific association of PTPN14 with BCC is related to our observation that PTPN14 loss activates YAP1 in basal epithelial cells. YAP1 inhibition is of major clinical interest for several cancer types, and it is appealing to speculate that targeting YAP1 could treat persistent HPV infection and/or HPV-positive cancers.

Materials and Methods

Plasmids and cloning. pInducer20 EGFP-TEADi was a gift from Ramiro Iglesias-Bartolome (Addgene plasmid # 140145) (Yuan et al., 2020). pQCXIH-Myc-YAP (Addgene plasmid # 33091), pQCXIH-Flag-YAP-S127A (Addgene plasmid # 33092), and pQCXIH-Myc-YAP-S94A (Addgene plasmid # 33094) were gifts from Kun-Liang Guan (Zhao et al., 2007). Each YAP1 ORF was amplified by PCR from pQCXIH, cloned into pDONR223, and transferred into pLIX_402 lentiviral backbone using Gateway recombination. pLIX_402 was a gift from David Root (Addgene plasmid # 41394). pLenti CMV GFP Hygro (656-4) was a gift from Eric Campeau & Paul Kaufman (Addgene plasmid # 17446) (Campeau et al., 2009). PHAGE-P-CMVt N-HA GFP was previously described (Galligan et al., 2014). pNeo-loxP-HPV18 was the kind gift of Thomas Broker and Louise Chow (Wang et al., 2009). The Δ DLLC mutation was introduced into the pDONR HPV18 E7 vector using site-directed mutagenesis. HPV18 E7 Δ DLLC and GFP ORFs were cloned into MSCV-P C-FlagHA GAW or MSCV-Neo C-HA GAW destination vectors using Gateway recombination. The remaining MSCV-P C-FlagHA and MSCV-Neo C-HA HPV E6 and HPV E7 retroviral plasmids and pHAGE lentiviral plasmids have been previously described (Hatterschide et al., 2020; White et al., 2016, 2012a, 2012b). A complete list of all plasmids used in this study is in [Supplemental File 1](#).

Cell culture, retrovirus production, and lentivirus production. Deidentified primary human foreskin keratinocytes (HFK) and human foreskin fibroblasts (HFF) were provided by the University of Pennsylvania Skin Biology and Disease Resource-Based Center (SBDRC). N/Tert-1 cells are hTert-immortalized HFK (Dickson et al., 2000), and N/Tert-Cas9 mock and sgPTPN14-1 are N/Tert-1 cells further engineered to constitutively express Cas9 (Hatterschide et al., 2019). Keratinocytes for cell fate experiments were cultured in keratinocyte serum-free media (KSFM) (Life Technologies, Carlsbad, California) mixed 1:1 with Medium 154 (Thermo Fisher Scientific, Waltham, Massachusetts) with the human keratinocyte growth supplement (HKGS) (Thermo

Fisher Scientific) (Duperret et al., 2015; Egolf et al., 2019). Keratinocytes for all other experiments were cultured as previously described (White et al., 2012a). HFF were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher Scientific) supplemented with antibiotic and antimycotic. HFK harboring the HPV18 genome were previously described (Hatterschide et al., 2020), and were generated by transfecting cells with the pNeo-loxP-HPV18 vector (Wang et al., 2009) along with NLS-Cre and selecting with G418 to generate a stable population. Lentiviruses and retroviruses were produced in 293T or 293 Phoenix cells respectively as previously described (White et al., 2016). Stable keratinocyte populations were generated following transduction by selection with puromycin, G418, or hygromycin alone or in combination.

Lifespan extension assay. Primary HFK were engineered and cultured as described in cell culture, retrovirus production, and lentivirus production. The growth of engineered HFK was monitored in culture for 38 days. Population doublings were calculated using the number of cells at the beginning and end of each passage.

Organotypic epithelial culture. Devitalized human dermis was provided as deidentified material from the University of Pennsylvania SBDRC. Stands for organotypic epithelial cultures were printed using high temperature, autoclavable resin at the University of Pennsylvania Biotech Commons 3D-printing facility. Organotypic cultures were generated as previously described (Duperret et al., 2015; Egolf et al., 2019). Devitalized dermis was seeded with primary HFF on the dermal side at a density of 3×10^4 cells per cm^2 of culturing area and cultured for four days. Dermis and fibroblasts were then stretched across 3D-printed stands. The epidermal side of the dermis was seeded with unmodified or engineered keratinocytes at a density of 1×10^6 cells per cm^2 . Organotypic cultures were cultured in E media (Fehrmann and Laimins, 2005) with the dermal layer maintained at the air-liquid interface starting on the day of seeding keratinocytes. Cultures were allowed to stratify for 12-14 days, then trimmed and fixed in 10% neutral buffer

formalin for 24 hours. Tissues were embedded in paraffin and sectioned by the SBDRC Core A.
A complete list of all organotypic cultures used in this study is in [Supplemental File 2](#).

siRNA transfection. Primary HFK were transfected with siRNAs using the Dharmafect 1 transfection reagent. All siRNA experiments were collected 72 h post transfection. Two siRNAs were used to target each gene in an experiment. The siRNAs used in this study were all purchased from Dharmacon (Lafayette, Colorado): nontargeting siRNA, siYAP1-06, siYAP1-08, siWWTR1-06, siWWTR1-08, siPTPN14-05, siPTPN14-08, siLATS1-05, siLATS1-08, siLATS2-09, siLATS2-10.

Laser capture microdissection. Formalin-fixed paraffin-embedded (FFPE) organotypic cultures were sectioned onto polyethylene naphthalate (PEN) membrane glass slides by the SBDRC Core A. Laser capture microdissection was performed on a Leica LMD 7000 microscope. Hundreds of microdissections were made per sample amounting to ~1.5 mm² of total dissected area per sample. RNA was isolated using the RNeasy FFPE kit (Qiagen, Germantown, Maryland). RNA concentration was determined using Qubit RNA HS assay kit (Life Technologies).

Patient derived xenografts. The PDXs were previously established from surgical resections of treatment-naïve HPV-positive OPSCC as described (Facompre et al., 2020). Human tumors were engrafted subcutaneously in NSG mice and passaged at least twice before cryopreservation when they reached a volume of 0.5-1.0 cm³. Total tumor RNA was isolated using the QIAamp RNA Blood Mini Kit (Qiagen).

Western blotting. Western blots were performed using Mini-PROTEAN (Bio-Rad Laboratories, Hercules, California) or Criterion (Bio-Rad) Tris/Glycine SDS-PAGE gels and transfers were performed onto polyvinylidene difluoride (PVDF). Membranes were blocked with 5% nonfat dried

milk in Tris-buffered saline with 0.05% Tween 20 (TBST). Membranes were incubated with primary antibodies as specified in [Supplemental File 1](#). Following TBST washes, membranes were incubated with horseradish peroxidase-coupled secondary antibodies and imaged using chemiluminescent substrate on an Amersham Imager 600 (GE Healthcare, Chicago, Illinois).

qRT-PCR. Unless otherwise specified, total cellular RNA was isolated using the NucleoSpin RNA extraction kit (Macherey-Nagel/Takara, San Jose, California). cDNA was generated from bulk RNA with the high-capacity cDNA reverse transcription kit (Applied Biosystems, Waltham, Massachusetts). cDNAs were used as a template for qPCR using Fast SYBR green master mix (Applied Biosystems) and a QuantStudio 3 system (Thermo Fisher Scientific). 18S rRNA qRT-PCR primers were ordered from Integrated DNA Technologies (Integrated DNA Technologies, Inc., Coralville, Iowa): FWD, 5'- CGCCGCTAGAGGTGAAATTCT; REV, 5'- CGAACCTCCGACTTTCGTTCT (Roh et al., 2005). KiCqStart SYBR green primers for qRT-PCR (MilliporeSigma, St. Louis, Missouri) were used for the remaining genes assayed in this study: KRT1, KRT10, IVL, ITGB4, ITGA6, CYR61, CTGF, PTPN14, YAP1, WWTR1, LATS1, LATS2, G6PD, and GAPDH.

Immunofluorescence, immunohistochemistry, and microscopy. FFPE sections were prepared for immunofluorescence by deparaffinization with xylene washes, rehydration through an ethanol gradient, and heat induced epitope retrieval (HIER). Tissue sections were blocked with PBS containing 1% bovine serum albumin, 10% normal goat serum, and 0.3% Triton X-100. Tissue sections were incubated with primary antibodies at 4°C overnight, washed with PBS with 0.05% Tween 20, and incubated with fluorescently labeled secondary antibodies and Hoechst 33342 at room temperature. Antibody dilutions and HIER conditions are specified in [Supplemental File 1](#). Fluorescent micrographs were captured using an Olympus IX81 microscope. All

fluorescent micrograph images within the same figure panels were captured using the same exposure time and batch processed using the same contrast settings.

The TMA was constructed from surgical resection specimens of 120 HNSCC that vary by TNM stage and HPV status ([Supplemental File 3](#)). Archival FFPE tumors of the oral cavity and oropharynx were identified retrospectively and oropharyngeal tumors were evaluated for HPV status as per College of American Pathologists criteria (Lewis et al., 2018) using IHC for p16. When present, lymph node metastases were included in association with the primary tumor of origin. All FFPE specimens were represented in the TMA by at least three tissue cores that incorporate both non-necrotic central tumor regions and invasive margins. Tumor materials and clinical data were accessed under University of Pennsylvania IRB protocol 417200. Staining for KRT1 was performed by the Clinical Services Laboratory in the University of Pennsylvania Department of Pathology and Laboratory Medicine. Antibody information can be found in [Supplemental File 1](#). The KRT1 stained slides were reviewed with a standard light microscope, and evaluation was based on the presence or absence of staining in the cytoplasm of tumor cells.

Bioinformatic analysis. Genomic mutation and copy number variation data as well as tumor RNA-seq gene expression data from TCGA (Lawrence et al., 2015) were analyzed using the cBioPortal.org graphical interface (Cerami et al., 2012; Gao et al., 2013). RNA-seq V2 RSEM (RNA-Seq by Expectation Maximization) normalized expression values for individual genes were downloaded directly from cBioPortal.org. OPSCC were distinguished from HNSCC by clinical annotation of primary tumor site and HPV-positive and HPV-negative status was assigned based on previously reported HPV transcript status (Chakravarthy et al., 2016). Genes included as a part of each pathway analysis are listed in [Supplemental File 4](#). Missense, truncating, and splice mutations of unknown significance as well as amplifications of tumor suppressor genes and deletion of oncogenes were excluded from total alteration tallies.

542 Single cell-RNA sequencing dataset derived from the human neonatal foreskin epidermis
543 and subsequent clustering analysis were retrieved from GitHub (S. Wang et al., 2020) and
544 reanalyzed with MATLAB. PTPN14 expression was calculated by averaging mRNA expression
545 for all cells by cluster and donor.
546

Acknowledgments

We thank the members of our laboratories, particularly Pavithra Rajagopalan, for helpful discussions. We thank Stephen M. Prouty, Ph.D. from the SBDRC for help with tissue processing and sectioning. Stands for organotypic cultures were printed courtesy of the University of Pennsylvania Libraries' Biotech Commons. This work was supported by American Cancer Society grant 131661-RSG-18-048-01-MPC and NIH/NIAID R01 AI148431 to EAW. DB is supported by NIH/NIDCR R01 DE027185. JH was supported by NIH/NIAID T32 AI007324 and NIH/NIDCR F31 DE030365. SBDRC was funded by NIH grant P30 AR068589.

Author Contributions

Conception and design: JH, EAW. Acquisition of data: JH, PC, HWK, KTM, EAW. Analysis and interpretation of data: JH, PC, KTM, DB, EAW. Drafting or revising the article: JH, PC, DB, EAW. Contributing unpublished essential data or reagents: SMS, KTM, DB.

Figure Legends

Figure 1 | HPV E7 activates YAP1 in basal epithelial keratinocytes. (A) cBioPortal analysis for total genomic mutations and copy number alterations in HPV+/- OPSCC and HNSCC. Graph displays the percent of tumors with alterations in each pathway. Statistical significance was determined by Fisher's exact test. (B-D) Organotypic cultures were grown from primary HFK, HFK harboring the HPV18 genome, or HFK transduced with retroviral expression encoding HPV E6 or E7 proteins. FFPE sections of cultures grown from (C) HFK or HFK harboring the HPV18 genome, (D) HFK or HFK expressing HPV16 E7 or HPV18 E7, or (E) HFK or HFK expressing HPV16 E6 or HPV16 E7 were stained for YAP1 (magenta), PCNA (green), and Hoechst (gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μ m. Inset scale bars = 25 μ m.

Figure 2 | HPV E7 activates YAP1 in basal keratinocytes through PTPN14 degradation. Organotypic cultures were grown from N/Tert-Cas9 keratinocytes or primary HFK transduced with retroviral expression vectors encoding HPV18 E7 WT or R84S. (A) FFPE sections of cultures grown from mock or sgPTPN14 transfected N/Tert-Cas9 keratinocytes were stained for YAP1 (magenta), IVL (green), and Hoechst (Gray). (B) FFPE sections of cultures grown from parental HFK, HPV18 E7 WT or HPV18 E7 R84S expressing HFK were stained for YAP1 (magenta), PCNA (green), and Hoechst (Gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μ m. Inset scale bars = 25 μ m. (C-F) Quantification of the number of (C and E) basal cells and (D and F) suprabasal cells per 100 μ m of epidermis. Graphs display the mean $\pm$ SD and each individual data point (independent cultures). Statistical significance was determined by ANOVA (* p <0.05, *** p <0.001).

Figure 3 | PTPN14 expression is enriched in basal keratinocytes. (A-B) Single-cell RNA sequencing data and clustering analysis from Wang et al. was reanalyzed to assess PTPN14

expression in different subsets of epidermal cells. (A) Diagram of epidermis; shading depicts tissue localization of cell clusters. (B) For each donor, the mean of PTPN14 mRNA expression was calculated for each cell cluster. Graphs display the mean of PTPN14 mRNA expression for each donor (circles) as well as the mean of all five donors $\pm$ SEM (bars and error bars). Statistical significance was determined by ANOVA (* $p < 0.05$, ** $p < 0.01$). (C-F) Basal and suprabasal layers from organotypic cultures were dissected using laser capture microdissection. (C) Representative images of HFK cultures before and after individual laser dissections. Hundreds of such cuts were performed per sample. (D-F) RNA was purified from isolated layers and qRT-PCR was used to assess the expression of PTPN14 (D), basal cell markers ITGA6 and ITGB4 (E), and differentiation markers KRT1 and IVL (F). Graphs display the mean and each individual data point.

Figure 4 | YAP1/TAZ regulate differentiation downstream of PTPN14. (A) Venn diagram comparing the MSigDB YAP conserved signature to the differentially expressed genes (DEG) from our two published experiments that reflect PTPN14 loss in keratinocytes. (B-D) *YAP1* and *WWTR1* were simultaneously knocked down by siRNA transfection in HFK. Transfected HFK were then transduced with PTPN14 lentivirus at 24h post transfection. Cells were lysed for protein and total cellular RNA at 72h post transfection. (B) Cell lysates were subjected to SDS/PAGE/Western analysis and probed with antibodies to PTPN14, YAP1, TAZ, and Actin. (C and D) qRT-PCR was used to measure the expression of the differentiation markers *KRT1* and *IVL* relative to *G6PD*. Graphs display fold change in gene expression relative to the mock transduced cells. (E-I) Primary HFK were transfected with siRNAs targeting *YAP1*, *WWTR1* (TAZ), *PTPN14*, *LATS1*, and *LATS2*. Two siRNAs were used per target. qRT-PCR was used to measure gene expression for: the differentiation markers *IVL* (E) and *KRT1* (F), and the canonical YAP1/TAZ targets *CTGF* (G) and *CYR61* (H). Data confirming that individual siRNA transfections depleted intended transcripts is summarized in a heatmap of $\log_2$ (fold-change) levels (I). Bar

graphs display the mean $\pm$ SD of three independent replicates. Statistical significance was determined by ANOVA (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$).

Figure 5 | HPV-positive HNSCC are less differentiated than HPV-negative HNSCC. (A)

Human HNSCC tumor samples were stained for KRT1 (left). Scale bar = 100 μ m. Graph displays the percentage of tumors that were KRT1⁺ (right). Statistical significance was determined by Fisher's exact test. (B-C) Total RNA was purified from PDX samples and qRT-PCR was used to assess gene expression of (B) the differentiation markers KRT1, KRT10, and IVL and (C) the canonical YAP1/TAZ targets CTGF and CYR61. Statistical significance was determined by Mann-Whitney nonparametric test. (* $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$).

Figure 6 | High-risk HPV E7 requires YAP1/TAZ-TEAD transcriptional activity to extend the

lifespan of primary keratinocytes. Primary HFK were transduced with retroviruses encoding HPV16 E7, HPV18 E7, or GFP, plus pInducer20 TEADi lentivirus. Each cell population was cultured with or without 1 μ g/mL doxycycline in the media for 38 days and population doublings were tracked with each passage. Graph displays the mean $\pm$ SD of two independently transduced cell populations per condition.

Figure 7 | PTPN14 loss and YAP1 activation by HPV E7 promote basal cell retention in

organotypic cultures. Organotypic cultures were grown from GFP-labeled HFK mixed with unmodified HFK. (A-B) GFP-labeled HFK were transduced with lentiviral vectors encoding YAP1 WT, YAP1 S127A, or YAP1 S94A under the control of a doxycycline inducible promoter. GFP-labeled YAP1 cells were mixed 1:25 into unmodified HFK and organotypic cultures were grown from the mixture. Cultures were grown $\pm$ 1 μ g/mL doxycycline. (C-D) GFP-labeled HFK were transduced with LentiCRISPR v2 vectors encoding control or PTPN14 targeting sgRNAs. GFP-

labeled cells were mixed 1:25 into unmodified HFK and organotypic cultures were grown from the mixture. (E-F) GFP-labeled HFK were transduced with HPV18 E7 WT, HPV18 E7 R84S, or the empty vector (EV). GFP-labeled HPV18 E7 cells were mixed 1:50 into unmodified HFK and organotypic cultures were grown from the mixture. (A, C, E) FFPE sections of cultures were stained for GFP (green), IVL (grey), and Hoechst (blue). Scale bar = 100 μ m. (B, D, F) Quantification of the percentage of GFP+ cells found in the basal layer. Graphs display the mean $\pm$ SD and each individual data point (independent cultures). Shapes indicate cultures grown from different HFK donors. Statistical significance was determined by ANOVA. (* p <0.05, ** p <0.01).

Figure 1—figure supplement 1 | HPV-positive HNSCC have fewer Hippo pathway alterations and lower expression of differentiation genes. cBioPortal analysis for genomic mutations and copy number alterations in HPV+/- HNSCC and OPSCC. Oncoprint displays specific genomic alterations in individual tumor samples.

Figure 1—figure supplement 2 | HPV18 E7 activates YAP1 in basal keratinocytes. (A-B) Additional replicates of organotypic cultures grown from primary HFK or HFK harboring the HPV18 genome. FFPE sections were stained for YAP1 (magenta), PCNA (green), and Hoechst (gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μ m. Inset scale bars = 25 μ m.

Figure 1—figure supplement 3 | HPV E7 activates YAP1 in basal keratinocytes. Additional replicates of organotypic cultures grown from primary HFK or HFK transduced with retroviral expression encoding HPV E7 proteins. FFPE sections of cultures grown from (A) HFK or HFK expressing HPV16 E7 or HPV18 E7, (B) HFK or HFK transduced with HPV16 E7, or (E) HFK and HFK expressing HPV18 E7 were stained for YAP1 (magenta), PCNA (green), and Hoechst (gray).

White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μ m. Inset scale bars = 25 μ m.

Figure 1—figure supplement 4 | HPV E6 does not activate YAP1 in basal keratinocytes.

Additional replicates of organotypic cultures grown from primary HFK or HFK transduced with retroviral expression encoding HPV E6 or E7 proteins. FFPE sections were stained for YAP1 (magenta), PCNA (green), and Hoechst (gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μ m. Inset scale bars = 25 μ m.

Figure 2—figure supplement 1 | PTPN14 knockout activates YAP1 in basal keratinocytes.

Additional replicates of organotypic cultures grown from N/Tert-Cas9 keratinocytes (A-C) FFPE sections from mock or sgPTPN14 transfected N/Tert-Cas9 keratinocytes were stained for YAP1 (magenta), IVL (green), and Hoechst (Gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μ m. Inset scale bars = 25 μ m.

Figure 2—figure supplement 2 | HPV E7 activates YAP1 in basal keratinocytes through

PTPN14 degradation. Additional replicates of organotypic cultures grown from primary HFK transduced with retroviral expression vectors encoding HPV18 E7 WT or R84S. FFPE sections from parental HFK, HPV18 E7 WT or HPV18 E7 R84S expressing HFK were stained for YAP1 (magenta), PCNA (green), and Hoechst (Gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μ m. Inset scale bars = 25 μ m.

Figure 3—figure supplement 1 | PTPN14 expression is enriched in basal keratinocytes in HPV 18 E7 expressing organotypic cultures. Basal and suprabasal layers from a 3D organotypic culture grown from HFK transduced with a retroviral expression vector encoding HPV18 E7 were dissected using laser capture microdissection. RNA was purified from isolated layers and qRT-PCR was used to assess the expression of PTPN14 (A), the basal cell markers ITGA6 and ITGB4 (B), and the differentiation marker IVL (C). Graphs display individual data points.

Figure 4—figure supplement 1 | PTPN14 overexpression promotes differentiation in keratinocytes. NTert-Cas9 Mock and sgPTPN14-1 keratinocytes were transduced with lentiviruses encoding GFP or PTPN14 or the empty vector control. (A) Cell lysates were subjected to SDS/PAGE/Western analysis and probed with antibodies to PTPN14, V5-tag, Involucrin, and Actin. (B) qRT-PCR was used to measure the expression of the differentiation markers IVL and KRT10 relative to G6PD. Graphs display the mean $\pm$ SD of two independent replicates.

Figure 4—figure supplement 2 | YAP1 and TAZ are required for PTPN14 to promote keratinocyte differentiation. Primary HFK were transfected with control or YAP1 and WWTR1 targeting siRNAs then transduced with PTPN14 encoding lentivirus. qRT-PCR was used to measure the expression of the differentiation markers (A) KRT1 and (B) IVL relative to G6PD. Graphs portray the change in gene expression relative to siC. Graphs display the mean $\pm$ SD of three independent replicates. Statistical significance was determined by ANOVA (** $p < 0.01$, *** $p < 0.001$).

Figure 5—figure supplement 1 | HPV-positive HNSCC express lower levels of differentiation genes. RNA-seq data from TCGA were accessed through cBioPortal. Violin plots display the distribution in $\log_2$ mRNA expression of differentiation markers (A) KRT1, (B) KRT10,

and (C) IVL, and the canonical YAP1/TAZ targets (D) CTGF and (E) CYR61. Statistical significance was determined by Mann-Whitney nonparametric test. (**p<0.01, ***p<0.001, ****p<0.0001).

Figure 7—figure supplement 1 | PTPN14 degradation by HPV E7 promotes basal cell retention. (A-B) GFP-labeled HFK were transduced with YAP1 WT, YAP1 S127A, or YAP1 S94A under the control of a doxycycline inducible promoter. (A) GFP expression was confirmed by fluorescence microscopy. Scale bar = 100 μ m. (B) Total RNA was purified from monolayer cells +/- treatment with 1 μ g/mL doxycycline for 72h. qRT-PCR was used to assess gene expression of YAP1 and CTGF. (C-D) GFP-labeled HFK were transduced with retroviral vectors encoding HPV18 WT, HPV18 Δ DLLC, HPV18 E7 R84S, or the empty vector control (EV). (C) GFP expression was confirmed by fluorescence microscopy. Scale bar = 100 μ m. (D) Cell lysates were subjected to SDS/PAGE/Western analysis and probed with antibodies to PTPN14, RB1, and Actin. (E-F) GFP-labeled HFK were transduced with LentiCRISPR v2 sgNT-1, sgPTPN14-3, or sgPTPN14-4 vectors. (E) GFP expression was confirmed by fluorescence microscopy. Scale bar = 100 μ m (F) Cell lysates were subjected to SDS/PAGE/Western analysis and probed with antibodies to PTPN14 and Actin.

Figure 7—figure supplement 2 | HPV18 E7 can promote basal cell retention in the absence of RB1 binding. Organotypic cultures were grown from GFP-labeled cells mixed with unmodified HFK. GFP-labeled HFK were transduced with HPV18 E7 Δ DLLC or the empty vector (EV). GFP-labeled cells were mixed 1:50 into unmodified HFK. (A) FFPE sections were stained for GFP (green), IVL (grey), and Hoechst (blue). Scale bar = 100 μ m (B) Quantification of the percentage of GFP+ cells found in the basal layer. Graphs display the mean $\pm$ SD and each individual data point (independent cultures). Statistical significance was determined by t-test. (**p<0.01).

References

- Alzahrani F, Clattenburg L, Muruganandan S, Bullock M, MacIsaac K, Wigerius M, Williams BA, Graham MER, Rigby MH, Trites JRB, Taylor SM, Sinal CJ, Fawcett JP, Hart RD. 2017. The Hippo component YAP localizes in the nucleus of human papilloma virus positive oropharyngeal squamous cell carcinoma. *Journal of Otolaryngology - Head and Neck Surgery* **46**. doi:10.1186/s40463-017-0187-1
- Balsitis S, Dick F, Dyson N, Lambert PF. 2006. Critical Roles for Non-pRb Targets of Human Papillomavirus Type 16 E7 in Cervical Carcinogenesis. *Cancer Res* **66**:9393–400. doi:10.1158/0008-5472.CAN-06-0984
- Balsitis S, Dick F, Lee D, Farrell L, Hyde RK, Griep AE, Dyson N, Lambert PF. 2005. Examination of the pRb-Dependent and pRb-Independent Functions of E7 In Vivo. *Journal of Virology* **79**:11392–11402. doi:10.1128/jvi.79.17.11392-11402.2005
- Banks L, Edmonds C, Vousden KH. 1990. Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. *Oncogene* **5**:1383–9.
- Beverdam A, Claxton C, Zhang X, James G, Harvey KF, Key B. 2013. Yap Controls Stem/Progenitor Cell Proliferation in the Mouse Postnatal Epidermis. *Journal of Investigative Dermatology* **133**:1497–1505. doi:10.1038/JID.2012.430
- Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, Seplyarskiy VB, Sharpe HJ, McKee T, Letourneau A, Ribaux PG, Popadin K, Basset-Seguín N, Chaabene R ben, Santoni FA, Andrianova MA, Guipponi M, Garieri M, Verdan C, Grosdemange K, Sumara O, Eilers M, Aifantis I, Michielin O, de Sauvage FJ, Antonarakis SE, Nikolaev SI. 2016. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. *Nature Genetics* **48**:398–406. doi:10.1038/ng.3525
- Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, Campisi J, Yaswen P, Cooper PK, Kaufman PD. 2009. A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells. *PLOS ONE* **4**:e6529. doi:10.1371/JOURNAL.PONE.0006529
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. 2012. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. *Cancer Discovery* **2**:401–404. doi:10.1158/2159-8290.CD-12-0095
- Chakravarthy A, Henderson S, Thirdborough SM, Ottensmeier CH, Su X, Lechner M, Feber A, Thomas GJ, Fenton TR. 2016. Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx. <https://doi.org/10.1200/JCO.2016.68.2955> **34**:4132–4141. doi:10.1200/JCO.2016.68.2955
- Ciccolini F, di Pasquale G, Carlotti F, Crawford L, Tommasino M. 1994. Functional studies of E7 proteins from different HPV types. *Oncogene* **9**:2633–8.

Collins AS, Nakahara T, Do A, Lambert PF. 2005. Interactions with pocket proteins contribute to the role of human papillomavirus type 16 E7 in the papillomavirus life cycle. *J Virol* **79**:14769–80. doi:10.1128/JVI.79.23.14769-14780.2005

Day PM, Schelhaas M. 2014. Concepts of papillomavirus entry into host cells. *Current Opinion in Virology* **4**:24–31. doi:10.1016/J.COVIRO.2013.11.002

de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. 2020. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. *The Lancet Global Health* **8**:e180–e190. doi:10.1016/S2214-109X(19)30488-7/ATTACHMENT/BC543EDD-015D-48D3-A3FB-6DFCF0BCDE7F/MMC1.PDF

de Martel C, Plummer M, Vignat J, Franceschi S. 2017. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *International Journal of Cancer* **141**:664–670. doi:10.1002/ijc.30716

Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP, Rheinwald JG. 2000. Human Keratinocytes That Express hTERT and Also Bypass a p16INK4a-Enforced Mechanism That Limits Life Span Become Immortal yet Retain Normal Growth and Differentiation Characteristics. *Molecular and Cellular Biology* **20**:1436–1447. doi:10.1128/mcb.20.4.1436-1447.2000

Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. 2015. Human papillomavirus molecular biology and disease association. *Reviews in Medical Virology* **25**:2–23. doi:10.1002/rmv.1822

Duperret EK, Dahal A, Ridky TW. 2015. Focal-adhesion-independent integrin-av regulation of FAK and c-Myc is necessary for 3D skin formation and tumor invasion. *Journal of Cell Science* **128**:3997–4013. doi:10.1242/jcs.175539

Egawa N, Nakahara T, Ohno S -i., Narisawa-Saito M, Yugawa T, Fujita M, Yamato K, Natori Y, Kiyono T. 2012. The E1 Protein of Human Papillomavirus Type 16 Is Dispensable for Maintenance Replication of the Viral Genome. *Journal of Virology*. doi:10.1128/JVI.06450-11

Egolf S, Aubert Y, Doepner M, Anderson A, Maldonado-Lopez A, Pacella G, Lee J, Ko EK, Zou J, Lan Y, Simpson CL, Ridky T, Capell BC. 2019. LSD1 Inhibition Promotes Epithelial Differentiation through Derepression of Fate-Determining Transcription Factors. *Cell Reports* **28**:1981-1992.e7. doi:10.1016/j.celrep.2019.07.058

Elbediwy A, Thompson BJ. 2018. Evolution of mechanotransduction via YAP/TAZ in animal epithelia. *Current Opinion in Cell Biology*. doi:10.1016/j.ceb.2018.02.003

Elbediwy A, Vincent-Mistiaen ZI, Spencer-Dene B, Stone RK, Boeing S, Wculek SK, Cordero J, Tan EH, Ridgway R, Brunton VG, Sahai E, Gerhardt H, Behrens A, Malanchi I, Sansom OJ, Thompson BJ. 2016. Integrin signalling regulates YAP and TAZ to control skin homeostasis. *Development (Cambridge, England)* **143**:1674–87. doi:10.1242/dev.133728

Facompre ND, Rajagopalan P, Sahu V, Pearson AT, Montone KT, James CD, Gleber-Netto FO, Weinstein GS, Jalaly J, Lin A, Rustgi AK, Nakagawa H, Califano JA, Pickering CR, White EA, Windle BE, Morgan IM, Cohen RB, Gimotty PA, Basu D. 2020. Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through

817 patient-derived models. *International Journal of Cancer* **147**:3236–3249.
818 doi:10.1002/IJC.33125

819 Fehrmann F, Laimins LA. 2005. Human Papillomavirus Type 31 Life Cycle Methods for
820 Studying Using Tissue Culture Models. *Methods in Molecular Biology* **292**:317–330.

821 Flores ER, Allen-Hoffmann BL, Lee D, Lambert PF. 2000. The human papillomavirus type 16 E7
822 oncogene is required for the productive stage of the viral life cycle. *Journal of virology*
823 **74**:6622–31. doi:10.1128/JVI.74.14.6622-6631.2000

824 Galligan JT, Martinez-Noël G, Arndt V, Hayes S, Chittenden TW, Harper JW, Howley PM. 2014.
825 Proteomic Analysis and Identification of Cellular Interactors of the Giant Ubiquitin Ligase
826 HERC2. *Journal of Proteome Research* **14**:953–966. doi:10.1021/PR501005V

827 Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R,
828 Larsson E, Cerami E, Sander C, Schultz N. 2013. Integrative Analysis of Complex Cancer
829 Genomics and Clinical Profiles Using the cBioPortal. *Science Signaling* **6**:1–1.
830 doi:10.1126/SCISIGNAL.2004088

831 Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. 2015. Epidemiology of Human
832 Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. *J Clin Oncol* **33**:3235–
833 3242. doi:10.1200/JCO.2015.61.6995

834 Graham S v. 2017. The human papillomavirus replication cycle, and its links to cancer
835 progression: a comprehensive review. *Clinical Science* **131**:2201–2221.
836 doi:10.1042/CS20160786

837 Halbert CL, Demers GW, Galloway DA. 1991. The E7 gene of human papillomavirus type 16 is
838 sufficient for immortalization of human epithelial cells. *Journal of virology* **65**:473–8.

839 Hatterschide J, Bohidar AE, Grace M, Nulton TJ, Kim HW, Windle B, Morgan IM, Munger K,
840 White EA. 2019. PTPN14 degradation by high-risk human papillomavirus E7 limits
841 keratinocyte differentiation and contributes to HPV-mediated oncogenesis. *Proceedings of*
842 *the National Academy of Sciences of the United States of America* **116**:7033–7042.
843 doi:10.1073/pnas.1819534116

844 Hatterschide J, Brantly AC, Grace M, Munger K, White EA. 2020. A Conserved Amino Acid in
845 the C Terminus of Human Papillomavirus E7 Mediates Binding to PTPN14 and Repression
846 of Epithelial Differentiation. *Journal of Virology* **94**. doi:10.1128/jvi.01024-20

847 He C, Lv X, Huang C, Angeletti PC, Hua G, Dong J, Zhou J, Wang Z, Ma B, Chen X, Lambert
848 PF, Rueda BR, Davis JS, Wang C. 2019. A Human Papillomavirus-Independent Cervical
849 Cancer Animal Model Reveals Unconventional Mechanisms of Cervical Carcinogenesis.
850 *Cell Reports* **26**. doi:10.1016/j.celrep.2019.02.004

851 He C, Mao D, Hua G, Lv X, Chen X, Angeletti PC, Dong J, Remmenga SW, Rodabaugh KJ,
852 Zhou J, Lambert PF, Yang P, Davis JS, Wang C. 2015. The Hippo/YAP pathway interacts
853 with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. *EMBO*
854 *molecular medicine* **7**:1426–49. doi:10.15252/emmm.201404976

855 Heck D v, Yee CL, Howley PM, Münger K. 1992. Efficiency of binding the retinoblastoma protein
856 correlates with the transforming capacity of the E7 oncoproteins of the human

papillomaviruses. *Proceedings of the National Academy of Sciences of the United States of America* **89**:4442–6. doi:10.1073/PNAS.89.10.4442

Helt A-MA-M, Galloway DA. 2002. Destabilization of the Retinoblastoma Tumor Suppressor by Human Papillomavirus Type 16 E7 Is Not Sufficient To Overcome Cell Cycle Arrest in Human Keratinocytes. *JOURNAL OF VIROLOGY* **75**:6737–6747. doi:10.1128/JVI.75.15.6737-6747.2001

Heng BC, Zhang X, Aubel D, Bai Y, Li X, Wei Y, Fussenegger M, Deng X. 2020. Role of YAP/TAZ in Cell Lineage Fate Determination and Related Signaling Pathways. *Frontiers in Cell and Developmental Biology* **0**:735. doi:10.3389/FCELL.2020.00735

Hicks-Berthet J, Ning B, Federico A, Tilston-Lunel A, Matschulat A, Ai X, Lenburg ME, Beane J, Monti S, Varelas X. 2021. Yap/Taz inhibit goblet cell fate to maintain lung epithelial homeostasis. *Cell Reports* **36**. doi:10.1016/J.CELREP.2021.109347

Huh KW, DeMasi J, Ogawa H, Nakatani Y, Howley PM, Münger K. 2005. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. *Proceedings of the National Academy of Sciences of the United States of America* **102**:11492–11497. doi:10.1073/pnas.0505337102

Hwang JH, Pores Fernando AT, Faure N, Andrabi S, Adelmant G, Hahn WC, Marto JA, Schaffhausen BS, Roberts TM. 2014. Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. *Journal of virology* **88**:12055–64. doi:10.1128/JVI.01399-14

Ibaraki T, Satake M, Kurai N, Ichijo M, Ito Y. 1993. Transacting activities of the E7 genes of several types of human papillomavirus. *Virus Genes* **7**:187–196. doi:10.1007/BF01702398

Jewers RJ, Hildebrandt P, Ludlow JW, Kell B, McCance DJ. 1992. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. *Journal of virology* **66**:1329–35.

Kho E-Y, Wang H-K, Banerjee NS, Broker TR, Chow LT. 2013. HPV-18 E6 mutants reveal p53 modulation of viral DNA amplification in organotypic cultures. *Proceedings of the National Academy of Sciences* **110**:7542–7549. doi:10.1073/PNAS.1304855110

Knight JF, Sung VYC, Kuzmin E, Couzens AL, de Verteuil DA, Ratcliffe CDH, Coelho PP, Johnson RM, Samavarchi-Tehrani P, Gruosso T, Smith HW, Lee W, Saleh SM, Zuo D, Zhao H, Guiot MC, Davis RR, Gregg JP, Moraes C, Gingras AC, Park M. 2018. KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer. *Cell Reports* **22**:3191–3205. doi:10.1016/j.celrep.2018.02.095

Knox KK, Carrigan DR. 1992. In Vitro Suppression of Bone Marrow Progenitor Cell Differentiation by Human Herpesvirus 6 Infection. *The Journal of Infectious Diseases* **165**:925–928. doi:10.1093/INFDIS/165.5.925

Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. 2008. Persistent human papillomavirus infection and cervical neoplasia: A systematic review and meta-analysis. *American Journal of Epidemiology*. doi:10.1093/aje/kwn036

Kranjec C, Holleywood C, Libert D, Griffin H, Mahmood R, Isaacson E, Doorbar J. 2017. Modulation of basal cell fate during productive and transforming HPV-16 infection is mediated by progressive E6-driven depletion of Notch. *The Journal of Pathology* **242**:448–462. doi:10.1002/path.4917

Lawrence MS, Sougnez C, Lichtenstein L, Cibulskis K, Lander E, Gabriel SB, Getz G, Ally A, Balasundaram M, Birol I, Bowlby R, Brooks D, Butterfield YSN, Carlsen R, Cheng D, Chu A, Dhalla N, Guin R, Holt RA, Jones SJM, Lee D, Li H, Marra MA, Mayo M, Moore RA, Mungall AJ, Robertson AG, Schein JE, Sipahimalani P, Tam A, Thiessen N, Wong T, Protopopov A, Santoso N, Lee S, Parfenov M, Zhang Jianhua, Mahadeshwar HS, Tang J, Ren X, Seth S, Haseley P, Zeng D, Yang Lixing, Xu AW, Song X, Pantazi A, Bristow CA, Hadjipanayis A, Seidman J, Chin L, Park PJ, Kucherlapati R, Akbani R, Casasent T, Liu W, Lu Y, Mills G, Motter T, Weinstein J, Diao L, Wang J, Hong Fan Y, Liu J, Wang K, Auman JT, Balu S, Bodenheimer T, Buda E, Hayes DN, Hoadley KA, Hoyle AP, Jefferys SR, Jones CD, Kimes PK, Liu Yufeng, Marron JS, Meng S, Mieczkowski PA, Mose LE, Parker JS, Perou CM, Prins JF, Roach J, Shi Y, Simons J v., Singh D, Soloway MG, Tan D, Veluvolu U, Walter V, Waring S, Wilkerson MD, Wu J, Zhao N, Cherniack AD, Hammerman PS, Tward AD, Peadarallu CS, Saksena G, Jung J, Ojesina AI, Carter SL, Zack TI, Schumacher SE, Beroukhir R, Freeman SS, Meyerson M, Cho J, Noble MS, DiCara D, Zhang H, Heiman DI, Gehlenborg N, Voet D, Lin P, Frazer S, Stojanov P, Liu Yingchun, Zou L, Kim J, Muzny D, Doddapaneni HV, Kovar C, Reid J, Morton D, Han Y, Hale W, Chao H, Chang K, Drummond JA, Gibbs RA, Kakkar N, Wheeler D, Xi L, Ciriello G, Ladanyi M, Lee W, Ramirez R, Sander C, Shen R, Sinha R, Weinhold N, Taylor BS, Aksoy BA, Dresdner G, Gao J, Gross B, Jacobsen A, Reva B, Schultz N, Sumer SO, Sun Y, Chan TA, Morris LG, Stuart J, Benz S, Ng S, Benz C, Yau C, Baylin SB, Cope L, Danilova L, Herman JG, Bootwalla M, Maglinte DT, Laird PW, Triche T, Weisenberger DJ, van den Berg DJ, Agrawal N, Bishop J, Boutros PC, Bruce JP, Byers LA, Califano J, Carey TE, Chen Z, Cheng H, Chiosea SI, Cohen E, Diergaarde B, Egloff AM, El-Naggar AK, Ferris RL, Frederick MJ, Grandis JR, Guo Y, Haddad RI, Harris T, Hui ABY, Lee JJ, Lippman SM, Liu FF, McHugh JB, Myers J, Ng PKS, Perez-Ordóñez B, Pickering CR, Prystowsky M, Romkes M, Saleh AD, Sartor MA, Seethala R, Seiwert TY, Si H, van Waes C, Waggott DM, Wiznerowicz M, Yarbrough WG, Zhang Jiexin, Zuo Z, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton C, Shelton T, Sherman M, Yena P, Black AD, Bowen J, Frick J, Gastier-Foster JM, Harper HA, Leraas K, Lichtenberg TM, Ramirez NC, Wise L, Zmuda E, Baboud J, Jensen MA, Kahn AB, Pihl TD, Pot DA, Srinivasan D, Walton JS, Wan Y, Burton RA, Davidsen T, Demchok JA, Eley G, Ferguson ML, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang Liming, Zenklusen JC, Saller C, Tarvin K, Chen C, Bollag R, Weinberger P, Golusiński W, Golusiński P, Ibbs M, Korski K, Mackiewicz A, Suchorska W, Szybiak B, Curley E, Beard C, Mitchell C, Sandusky G, Ahn J, Khan Z, Irish J, Waldron J, William WN, Egea S, Gomez-Fernandez C, Herbert L, Bradford CR, Chepeha DB, Haddad AS, Jones TR, Komarck CM, Malakh M, Moyer JS, Nguyen A, Peterson LA, Prince ME, Rozek LS, Taylor EG, Walline HM, Wolf GT, Boice L, Chera BS, Funkhouser WK, Gulley ML, Hackman TG, Hayward MC, Huang M, Rathmell WK, Salazar AH, Shockley WW, Shores CG, Thorne L, Weissler MC, Wrenn S, Zanation AM, Brown BT, Pham M. 2015. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2015 **517**:7536 **517**:576–582. doi:10.1038/nature14129

942 Lewis JS, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, Moncur JT, Rocco
943 JW, Schwartz MR, Seethala RR, Thomas NE, Westra WH, Faquin WC. 2018. Human
944 Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of
945 American Pathologists. *Archives of Pathology & Laboratory Medicine* **142**:559–597.
946 doi:10.5858/ARPA.2017-0286-CP

947 Liu G, Yu F-X, Kim YC, Meng Z, Naipauer J, Looney DJ, Liu X, Gutkind JS, Mesri EA, Guan K-
948 L. 2014. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating
949 the Hippo pathway. *Oncogene* **2015 34**:27 **34**:3536–3546. doi:10.1038/onc.2014.281

950 Liu K, Du S, Gao P, Zheng J. 2019. Verteporfin suppresses the proliferation, epithelial-
951 mesenchymal transition and stemness of head and neck squamous carcinoma cells via
952 inhibiting YAP1. *Journal of Cancer* **10**:4196–4207. doi:10.7150/jca.34145

953 Liu P, Zhang H, Liang X, Ma H, Luan F, Wang B, Bai F, Gao L, Ma C. 2015. HBV preS2
954 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of
955 hepatocellular carcinoma. *Oncotarget* **6**:29048. doi:10.18632/ONCOTARGET.4804

956 McBride AA. 2021. Human papillomaviruses: diversity, infection and host interactions. *Nature*
957 *Reviews Microbiology*. doi:10.1038/s41579-021-00617-5

958 McBride AA. 2017. Mechanisms and strategies of papillomavirus replication. *Biological*
959 *Chemistry* **398**:919–927. doi:10.1515/hsz-2017-0113

960 McLaughlin-Drubin ME, Bromberg-White JL, Meyers C. 2005. The role of the human
961 papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. *Virology* **338**:61–
962 68. doi:10.1016/j.virol.2005.04.036

963 Mello SS, Valente LJ, Raj N, Seoane JA, Flowers BM, McClendon J, Biegging-Rolett KT, Lee J,
964 Ivanochko D, Kozak MM, Chang DT, Longacre TA, Koong AC, Arrowsmith CH, Kim SK,
965 Vogel H, Wood LD, Hruban RH, Curtis C, Attardi LD. 2017. A p53 Super-tumor Suppressor
966 Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. *Cancer Cell*
967 **32**:460–473.e6. doi:10.1016/j.ccell.2017.09.007

968 Mendelsohn AH, Lai CK, Shintaku IP, Elashoff DA, Dubinett SM, Abemayor E, st. John MA.
969 2010. Histopathologic findings of HPV and p16 positive HNSCC. *The Laryngoscope*
970 **120**:1788–1794. doi:10.1002/lary.21044

971 Mirabello L, Yeager M, Yu K, Clifford GM, Xiao Y, Zhu B, Cullen M, Boland JF, Wentzensen N,
972 Nelson CW, Raine-Bennett T, Chen Z, Bass S, Song L, Yang Q, Steinberg M, Burdett L,
973 Dean M, Roberson D, Mitchell J, Lorey T, Franceschi S, Castle PE, Walker J, Zuna R,
974 Kreimer AR, Beachler DC, Hildesheim A, Gonzalez P, Porras C, Burk RD, Schiffman M.
975 2017. HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. *Cell* **170**:1164-
976 1174.e6.

977 Morgan EL, Patterson MR, Ryder EL, Lee SY, Wasson CW, Harper KL, Li Y, Griffin S, Blair GE,
978 Whitehouse A, Macdonald A. 2020. MicroRNA-18a targeting of the STK4/MST1 tumour
979 suppressor is necessary for transformation in HPV positive cervical cancer. *PLOS*
980 *Pathogens* **16**:e1008624. doi:10.1371/journal.ppat.1008624

981 Moroishi T, Hansen CG, Guan K-L. 2015. The emerging roles of YAP and TAZ in cancer.
982 *Nature Reviews Cancer* **15**:73–79. doi:10.1038/nrc3876

983 Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. 1989. Complex formation
984 of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene
985 product. *The EMBO Journal* **8**:4099–4105. doi:10.1002/j.1460-2075.1989.tb08594.x

986 Nguyen HT, Hong X, Tan S, Chen Q, Chan L, Fivaz M, Cohen SM, Voorhoeve PM. 2014. Viral
987 Small T Oncoproteins Transform Cells by Alleviating Hippo-Pathway-Mediated Inhibition of
988 the YAP Proto-oncogene. *Cell Reports* **8**:707–713. doi:10.1016/J.CELREP.2014.06.062

989 Niiya H, Lei J, Guo Y, Azuma T, Yakushijin Y, Sakai I, Hato T, Tohyama M, Hashimoto K,
990 Yasukawa M. 2006. Human herpesvirus 6 impairs differentiation of monocytes to dendritic
991 cells. *Experimental Hematology* **34**:642–653. doi:10.1016/J.EXPHEM.2006.02.001

992 Nishio M, To Y, Maehama T, Aono Y, Otani J, Hikasa H, Kitagawa A, Mimori K, Sasaki T,
993 Nishina H, Toyokuni S, Lydon JP, Nakao K, Mak TW, Kiyono T, Katabuchi H, Tashiro H,
994 Suzuki A. 2020. Endogenous YAP1 activation drives immediate onset of cervical
995 carcinoma in situ in mice. *Cancer Science* **111**:3576. doi:10.1111/CAS.14581

996 Olafsdottir T, Stacey SN, Sveinbjornsson G, Thorleifsson G, Norland K, Sigurgeirsson B,
997 Thorisdottir K, Kristjansson AK, Tryggvadottir L, Sarin KY, Benediktsson R, Jonasson JG,
998 Sigurdsson A, Jonasdottir A, Kristmundsdottir S, Jonsson H, Gylfason A, Oddsson A,
999 Fridriksdottir R, Gudjonsson SA, Zink F, Lund SH, Rognvaldsson S, Melsted P,
1000 Steinthorsdottir V, Gudmundsson J, Mikaelssdottir E, Olason PI, Stefansdottir L, Eggertsson
1001 HP, Halldorsson B v., Thorsteinsdottir U, Agustsson TT, Olafsson K, Olafsson JH, Sulem
1002 P, Rafnar T, Gudbjartsson DF, Stefansson K. 2021. Loss-of-Function Variants in the
1003 Tumor-Suppressor Gene PTPN14 Confer Increased Cancer Risk. *Cancer Research*
1004 **81**:1954–1964. doi:10.1158/0008-5472.CAN-20-3065

1005 Olmedo-Nieva L, Muoz-Bello JO, Manzo-Merino J, Lizano M. 2020. New insights in Hippo
1006 signalling alteration in human papillomavirus-related cancers. *Cellular Signalling* 109815.
1007 doi:10.1016/j.cellsig.2020.109815

1008 Omori H, Nishio M, Masuda M, Miyachi Y, Ueda F, Nakano T, Sato K, Mimori K, Taguchi K,
1009 Hikasa H, Nishina H, Tashiro H, Kiyono T, Mak TW, Nakao K, Nakagawa T, Maehama T,
1010 Suzuki A. 2020. YAP1 is a potent driver of the onset and progression of oral squamous cell
1011 carcinoma. *Science Advances* **6**:eaay3324. doi:10.1126/sciadv.aay3324

1012 Onnis A, Navari M, Antonicelli G, Morettini F, Mannucci S, de Falco G, Vigorito E, Leoncini L.
1013 2012. Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-
1014 miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights
1015 into the pathogenesis of Burkitt lymphoma. *Blood Cancer Journal* **2012** **2**:e84–e84.
1016 doi:10.1038/bcj.2012.29

1017 Pai SI, Westra WH. 2009. Molecular Pathology of Head and Neck Cancer: Implications for
1018 Diagnosis, Prognosis, and Treatment. *Annual Review of Pathology: Mechanisms of*
1019 *Disease* **4**:49–70. doi:10.1146/annurev.pathol.4.110807.092158

1020 Parish JL, Bean AM, Park RB, Androphy EJ. 2006. ChIR1 Is Required for Loading
1021 Papillomavirus E2 onto Mitotic Chromosomes and Viral Genome Maintenance. *Molecular*
1022 *Cell* **24**:867–876. doi:10.1016/j.molcel.2006.11.005

1023 Perez CA, Ott J, Mays DJ, Pietenpol JA. 2007. p63 consensus DNA-binding site: identification,
1024 analysis and application into a p63MH algorithm. *Oncogene* **26**:7363–7370.
1025 doi:10.1038/sj.onc.1210561

1026 Phelps WC, Munger K, Yee CL, Barnes JA, Howley PM. 1992. Structure-function analysis of the
1027 human papillomavirus type 16 E7 oncoprotein. *Journal of Virology* **66**:2418–2427.
1028 doi:10.1128/jvi.66.4.2418-2427.1992

1029 Poernbacher I, Baumgartner R, Marada SK, Edwards K, Stocker H. 2012. Drosophila Pex acts
1030 in Hippo signaling to restrict intestinal stem cell proliferation. *Current biology : CB* **22**:389–
1031 96. doi:10.1016/j.cub.2012.01.019

1032 Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. 2009. Establishment of human
1033 papillomavirus infection requires cell cycle progression. *PLoS Pathogens* **5**:e1000318.
1034 doi:10.1371/journal.ppat.1000318

1035 Radley D, Saah A, Stanley M. 2016. Persistent infection with human papillomavirus 16 or 18 is
1036 strongly linked with high-grade cervical disease. *Human Vaccines & Immunotherapeutics*
1037 **12**:768–772. doi:10.1080/21645515.2015.1088616

1038 Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT.
1039 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and
1040 inhibited by carrageenan. *Nature Medicine* **13**:7 13:857–861. doi:10.1038/nm1598

1041 Roh M, Song C, Kim J, Abdulkadir SA. 2005. Chromosomal Instability Induced by Pim-1 Is
1042 Passage-dependent and Associated with Dysregulation of Cyclin B1 *. *Journal of Biological*
1043 *Chemistry* **280**:40568–40577. doi:10.1074/JBC.M509369200

1044 Romeo MA, Gilardini Montani MS, Falcinelli L, Gaeta A, Nazzari C, Faggioni A, Cirone M. 2019.
1045 HHV-6B reduces autophagy and induces ER stress in primary monocytes impairing their
1046 survival and differentiation into dendritic cells. *Virus Research* **273**:197757.
1047 doi:10.1016/J.VIRUSRES.2019.197757

1048 Rositch AF, Koshiol J, Hudgens MG, Razzaghi H, Backes DM, Pimenta JM, Franco EL, Poole
1049 C, Smith JS. 2013. Patterns of persistent genital human papillomavirus infection among
1050 women worldwide: A literature review and meta-analysis. *International Journal of Cancer*
1051 **133**:1271–1285. doi:10.1002/ijc.27828

1052 Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadou S, Liu DL,
1053 Kantheti HS, Saghafeinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz
1054 SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang Hongxin, Kundra R,
1055 Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP,
1056 Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ,
1057 Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ,
1058 McCormick F, Meyerson M, Caesar-Johnson SJ, Demchok JA, Felau I, Kasapi M,
1059 Ferguson ML, Hutter CM, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J
1060 (Julia), Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Cho J,
1061 DeFreitas T, Frazer S, Gehlenborg N, Getz G, Heiman DI, Kim J, Lawrence MS, Lin P,
1062 Meier S, Noble MS, Saksena G, Voet D, Zhang Hailei, Bernard B, Chambwe N, Dhankani
1063 V, Knijnenburg T, Kramer R, Leinonen K, Liu Y, Miller M, Reynolds S, Shmulevich I,
1064 Thorsson V, Zhang W, Akbani R, Broom BM, Hegde AM, Ju Z, Kanchi RS, Korkut A, Li J,

1065 Liang H, Ling S, Liu W, Lu Y, Mills GB, Ng KS, Rao A, Ryan M, Wang Jing, Weinstein JN,
1066 Zhang J, Abeshouse A, Armenia J, Chakravarty D, Chatila WK, de Bruijn I, Gross BE,
1067 Heins ZJ, Kundra R, La K, Ladanyi M, Luna A, Nissan MG, Ochoa A, Phillips SM, Reznik
1068 E, Sanchez-Vega F, Sander C, Schultz N, Sheridan R, Sumer SO, Sun Y, Taylor BS,
1069 Wang Jioajiao, Zhang Hongxin, Anur P, Peto M, Spellman P, Benz C, Stuart JM, Wong
1070 CK, Yau C, Hayes DN, Parker JS, Wilkerson MD, Ally A, Balasundaram M, Bowlby R,
1071 Brooks D, Carlsen R, Chuah E, Dhalla N, Holt R, Jones SJM, Kasaian K, Lee D, Ma Y,
1072 Marra MA, Mayo M, Moore RA, Mungall AJ, Mungall K, Robertson AG, Sadeghi S, Schein
1073 JE, Sipahimalani P, Tam A, Thiessen N, Tse K, Wong T, Berger AC, Beroukhir R,
1074 Cherniack AD, Cibulskis C, Gabriel SB, Gao GF, Ha G, Meyerson M, Schumacher SE,
1075 Shih J, Kucherlapati MH, Kucherlapati RS, Baylin S, Cope L, Danilova L, Bootwalla MS, Lai
1076 PH, Maglinte DT, van den Berg DJ, Weisenberger DJ, Auman JT, Balu S, Bodenheimer T,
1077 Fan C, Hoadley KA, Hoyle AP, Jefferys SR, Jones CD, Meng S, Mieczkowski PA, Mose
1078 LE, Perou AH, Perou CM, Roach J, Shi Y, Simons J v., Skelly T, Soloway MG, Tan D,
1079 Veluvolu U, Fan H, Hinoue T, Laird PW, Shen H, Zhou W, Bellair M, Chang K, Covington
1080 K, Creighton CJ, Dinh H, Doddapaneni HV, Donehower LA, Drummond J, Gibbs RA, Glenn
1081 R, Hale W, Han Y, Hu J, Korchina V, Lee S, Lewis L, Li W, Liu X, Morgan M, Morton D,
1082 Muzny D, Santibanez J, Sheth M, Shinbrot E, Wang L, Wang M, Wheeler DA, Xi L, Zhao F,
1083 Hess J, Appelbaum EL, Bailey M, Cordes MG, Ding L, Fronick CC, Fulton LA, Fulton RS,
1084 Kandoth C, Mardis ER, McLellan MD, Miller CA, Schmidt HK, Wilson RK, Crain D, Curley
1085 E, Gardner J, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton C, Shelton T,
1086 Sherman M, Thompson E, Yena P, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM,
1087 Lichtenberg TM, Ramirez NC, Wise L, Zmuda E, Corcoran N, Costello T, Hovens C,
1088 Carvalho AL, de Carvalho AC, Fregnani JH, Longatto-Filho A, Reis RM, Scapulatempo-
1089 Neto C, Silveira HCS, Vidal DO, Burnette A, Eschbacher J, Hermes B, Noss A, Singh R,
1090 Anderson ML, Castro PD, Ittmann M, Huntsman D, Kohl B, Le X, Thorp R, Andry C, Duffy
1091 ER, Lyadov V, Paklina O, Setdikova G, Shabunin A, Tavobilov M, McPherson C, Warnick
1092 R, Berkowitz R, Cramer D, Feltmate C, Horowitz N, Kibel A, Muto M, Raut CP, Malykh A,
1093 Barnholtz-Sloan JS, Barrett W, Devine K, Fulop J, Ostrom QT, Shimmel K, Wolinsky Y,
1094 Sloan AE, de Rose A, Giulianti F, Goodman M, Karlan BY, Hagedorn CH, Eckman J, Harr
1095 J, Myers J, Tucker K, Zach LA, Deyarmin B, Hu H, Kvecher L, Larson C, Mural RJ, Somiari
1096 S, Vicha A, Zelinka T, Bennett J, Iacocca M, Rabeno B, Swanson P, Latour M, Lacombe L,
1097 Têtu B, Bergeron A, McGraw M, Staugaitis SM, Chabot J, Hibshoosh H, Sepulveda A, Su
1098 T, Wang T, Potapova O, Voronina O, Desjardins L, Mariani O, Roman-Roman S, Sastre X,
1099 Stern MH, Cheng F, Signoretti S, Berchuck A, Bigner D, Lipp E, Marks J, McCall S,
1100 McLendon R, Secord A, Sharp A, Behera M, Brat DJ, Chen A, Delman K, Force S, Khuri F,
1101 Magliocca K, Maithel S, Olson JJ, Owonikoko T, Pickens A, Ramalingam S, Shin DM, Sica
1102 G, van Meir EG, Zhang Hongzheng, Eijckenboom W, Gillis A, Korpershoek E, Looijenga L,
1103 Oosterhuis W, Stoop H, van Kessel KE, Zwarthoff EC, Calatozzolo C, Cuppini L, Cuzzubbo
1104 S, DiMeco F, Finocchiaro G, Mattei L, Perin A, Pollo B, Chen C, Houck J, Lohavanichbutr
1105 P, Hartmann A, Stoeckl R, Stoeckl R, Taubert H, Wach S, Wullich B, Kyrcle W, Murawa D,
1106 Wiznerowicz M, Chung K, Edenfield WJ, Martin J, Baudin E, Bubley G, Bueno R, de
1107 Rienzo A, Richards WG, Kalkanis S, Mikkelsen T, Noushmehr H, Scarpaccia L, Girard N,
1108 Aymerich M, Campo E, Giné E, Guillermo AL, van Bang N, Hanh PT, Phu BD, Tang Y,
1109 Colman H, Evason K, Dottino PR, Martignetti JA, Gabra H, Juhl H, Akeredolu T, Stepas S,
1110 Hoon D, Ahn K, Kang KJ, Beuschlein F, Breggia A, Birrer M, Bell D, Borad M, Bryce AH,
1111 Castle E, Chandan V, Cheville J, Copland JA, Farnell M, Flotte T, Giana N, Ho T, Kendrick

M, Kocher JP, Kopp K, Moser C, Nagorney D, O'Brien D, O'Neill BP, Patel T, Petersen G, Que F, Rivera M, Roberts L, Smallridge R, Smyrk T, Stanton M, Thompson RH, Torbenson M, Yang JD, Zhang L, Brimo F, Ajani JA, Gonzalez AMA, Behrens C, Bondaruk J, Broaddus R, Czerniak B, Esmaeli B, Fujimoto J, Gershenwald J, Guo C, Logothetis C, Meric-Bernstam F, Moran C, Ramondetta L, Rice D, Sood A, Tamboli P, Thompson T, Troncso P, Tsao A, Wistuba I, Carter C, Haydu L, Hersey P, Jakrot V, Kakavand H, Kefford R, Lee K, Long G, Mann G, Quinn M, Saw R, Scolyer R, Shannon K, Spillane A, Stretch J, Synott M, Thompson J, Wilmott J, Al-Ahmadie H, Chan TA, Ghossein R, Gopalan A, Levine DA, Reuter V, Singer S, Singh B, Tien NV, Broudy T, Mirsaidi C, Nair P, Drwiega P, Miller J, Smith J, Zaren H, Park JW, Hung NP, Kebebew E, Linehan WM, Metwalli AR, Pacak K, Pinto PA, Schiffman M, Schmidt LS, Vocke CD, Wentzensen N, Worrell R, Yang H, Moncrieff M, Goparaju C, Melamed J, Pass H, Botnariuc N, Caraman I, Cernat M, Chemencedji I, Clipca A, Doruc S, Gorincioi G, Mura S, Pirtac M, Stancul I, Tcaciuc D, Albert M, Alexopoulou I, Arnaout A, Bartlett J, Engel J, Gilbert S, Parfitt J, Sekhon H, Thomas G, Rassl DM, Rintoul RC, Bifulco C, Tamakawa R, Urba W, Hayward N, Timmers H, Antenucci A, Facciolo F, Grazi G, Marino M, Merola R, de Krijger R, Gimenez-Roqueplo AP, Piché A, Chevalier S, McKercher G, Birsoy K, Barnett G, Brewer C, Farver C, Naska T, Pennell NA, Raymond D, Schilero C, Smolenski K, Williams F, Morrison C, Borgia JA, Liptay MJ, Pool M, Seder CW, Junker K, Omberg L, Dinkin M, Manikhas G, Alvaro D, Bragazzi MC, Cardinale V, Carpino G, Gaudio E, Chesla D, Cottingham S, Dubina M, Moiseenko F, Dhanasekaran R, Becker KF, Janssen KP, Slotta-Huspenina J, Abdel-Rahman MH, Aziz D, Bell S, Cebulla CM, Davis A, Duell R, Elder JB, Hilty J, Kumar B, Lang J, Lehman NL, Mandt R, Nguyen P, Pilarski R, Rai K, Schoenfield L, Senecal K, Wakely P, Hansen P, Lechan R, Powers J, Tischler A, Grizzle WE, Sexton KC, Kastl A, Henderson J, Porten S, Waldmann J, Fassnacht M, Asa SL, Schadendorf D, Couce M, Graefen M, Huland H, Sauter G, Schlomm T, Simon R, Tennstedt P, Olabode O, Nelson M, Bathe O, Carroll PR, Chan JM, Disaia P, Glenn P, Kelley RK, Landen CN, Phillips J, Prados M, Simko J, Smith-McCune K, VandenBerg S, Roggin K, Fehrenbach A, Kendler A, Sifri S, Steele R, Jimeno A, Carey F, Forgie I, Mannelli M, Carney M, Hernandez B, Campos B, Herold-Mende C, Jungk C, Unterberg A, von Deimling A, Bossler A, Galbraith J, Jacobus L, Knudson M, Knutson T, Ma D, Milhem M, Sigmund R, Godwin AK, Madan R, Rosenthal HG, Adebamowo C, Adebamowo SN, Boussioutas A, Beer D, Giordano T, Mes-Masson AM, Saad F, Bocklage T, Landrum L, Mannel R, Moore K, Moxley K, Postier R, Walker J, Zuna R, Feldman M, Valdivieso F, Dhir R, Luketich J, Pinero EMM, Quintero-Aguilo M, Carlotti CG, dos Santos JS, Kemp R, Sankarankuty A, Tirapelli D, Catto J, Agnew K, Swisher E, Creaney J, Robinson B, Shelley CS, Godwin EM, Kendall S, Shipman C, Bradford C, Carey T, Haddad A, Moyer J, Peterson L, Prince M, Rozek L, Wolf G, Bowman R, Fong KM, Yang I, Korst R, Rathmell WK, Fantacone-Campbell JL, Hooke JA, Kovatich AJ, Shriver CD, DiPersio J, Drake B, Govindan R, Heath S, Ley T, van Tine B, Westervelt P, Rubin MA, Lee J il, Aredes ND, Mariamidze A, van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. 2018. Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell* **173**:321-337.e10.

doi:10.1016/J.CELL.2018.03.035

Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. *Cell* **63**:1129–1136. doi:10.1016/0092-8674(90)90409-8

1158 Schlegelmilch K, Mohseni M, Kirak O, Pruszek J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin
1159 V, Avruch J, Brummelkamp TR, Camargo FD. 2011. Yap1 acts downstream of α -catenin to
1160 control epidermal proliferation. *Cell* **144**:782–795. doi:10.1016/j.cell.2011.02.031

1161 Seavey SE, Holubar M, Saucedo LJ, Perry ME. 1999. The E7 Oncoprotein of Human
1162 Papillomavirus Type 16 Stabilizes p53 through a Mechanism Independent of p19ARF.
1163 *Journal of Virology* **73**:7590–7598. doi:10.1128/jvi.73.9.7590-7598.1999

1164 Shanzer M, Ricardo-Lax I, Keshet R, Reuven N, Shaul Y. 2015. The polyomavirus middle T-
1165 antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent
1166 manner. *Oncogene* **34**:4190–4198. doi:10.1038/onc.2014.347

1167 Strati K, Lambert PF. 2007. Role of Rb-dependent and Rb-independent functions of
1168 papillomavirus E7 oncogene in head and neck cancer. *Cancer Research* **67**:11585–11593.
1169 doi:10.1158/0008-5472.CAN-07-3007

1170 Styles CT, Bazot Q, Parker GA, White RE, Paschos K, Allday MJ. 2017. EBV epigenetically
1171 suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term
1172 latency. *PLOS Biology* **15**:e2001992. doi:10.1371/JOURNAL.PBIO.2001992

1173 Szalmás A, Tomaić V, Basukala O, Massimi P, Mittal S, Kónya J, Banks L. 2017. The PTPN14
1174 Tumor Suppressor Is a Degradation Target of Human Papillomavirus E7. *Journal of*
1175 *Virology* **91**:e00057-17. doi:10.1128/jvi.00057-17

1176 Szymaniak AD, Mahoney JE, Cardoso W v., Varelas X. 2015. Crumbs3-Mediated Polarity
1177 Directs Airway Epithelial Cell Fate through the Hippo Pathway Effector Yap. *Developmental*
1178 *Cell* **34**:283–296. doi:10.1016/J.DEVCEL.2015.06.020

1179 Tian Y, Li D, Dahl J, You J, Benjamin T. 2004. Identification of TAZ as a Binding Partner of the
1180 Polyomavirus T Antigens. *Journal of Virology* **78**:12657–12664.
1181 doi:10.1128/jvi.78.22.12657-12664.2004

1182 Totaro A, Castellan M, Battilana G, Zanconato F, Azzolin L, Giulitti S, Cordenonsi M, Piccolo S.
1183 2017. YAP/TAZ link cell mechanics to Notch signalling to control epidermal stem cell fate.
1184 *Nature Communications* **8**:1–13. doi:10.1038/ncomms15206

1185 Wang H-K, Duffy AA, Broker TR, Chow LT. 2009. Robust production and passaging of
1186 infectious HPV in squamous epithelium of primary human keratinocytes. *Genes &*
1187 *development* **23**:181–94. doi:10.1101/gad.1735109

1188 Wang S, Drummond ML, Guerrero-Juarez CF, Tarapore E, MacLean AL, Stabell AR, Wu SC,
1189 Gutierrez G, That BT, Benavente CA, Nie Q, Atwood SX. 2020. Single cell transcriptomics
1190 of human epidermis identifies basal stem cell transition states. *Nature Communications*
1191 **2020 11:1 11**:1–14. doi:10.1038/s41467-020-18075-7

1192 Wang W, Huang J, Wang X, Yuan J, Li X, Feng L, Park J il, Chen J. 2012. PTPN14 is required
1193 for the density-dependent control of YAP1. *Genes and Development* **26**:1959–1971.
1194 doi:10.1101/gad.192955.112

1195 Wang Z, Lu W, Zhang Y, Zou F, Jin Z, Zhao T. 2020. The Hippo Pathway and Viral Infections.
1196 *Frontiers in Microbiology* **0**:3033. doi:10.3389/FMICB.2019.03033

1197 Webb Strickland S, Brimer N, Lyons C, vande Pol SB. 2018. Human Papillomavirus E6
1198 interaction with cellular PDZ domain proteins modulates YAP nuclear localization. *Virology*
1199 **516**:127–138. doi:10.1016/J.VIROL.2018.01.003

1200 Werness BA, Levine AJ, Howley PM. 1990. Association of human papillomavirus types 16 and
1201 18 E6 proteins with p53. *Science* **248**:76–79. doi:10.1126/science.2157286

1202 White EA, Kramer RE, Hwang JH, Pores Fernando AT, Naetar N, Hahn WC, Roberts TM,
1203 Schaffhausen BS, Livingston DM, Howley PM. 2015. Papillomavirus E7 Oncoproteins
1204 Share Functions with Polyomavirus Small T Antigens. *Journal of Virology* **89**:2857–2865.
1205 doi:10.1128/jvi.03282-14

1206 White EA, Kramer RE, Tan MJA, Hayes SD, Harper JW, Howley PM. 2012a. Comprehensive
1207 Analysis of Host Cellular Interactions with Human Papillomavirus E6 Proteins Identifies
1208 New E6 Binding Partners and Reflects Viral Diversity. *Journal of Virology* **86**:13174–13186.
1209 doi:10.1128/JVI.02172-12

1210 White EA, Münger K, Howley PM. 2016. High-Risk Human Papillomavirus E7 Proteins Target
1211 PTPN14 for Degradation. *mBio* **7**:e01530-16. doi:10.1128/mBio.01530-16

1212 White EA, Sowa ME, Tan MJA, Jeudy S, Hayes SD, Santha S, Münger K, Harper JW, Howley
1213 PM. 2012b. Systematic identification of interactions between host cell proteins and E7
1214 oncoproteins from diverse human papillomaviruses. *Proceedings of the National Academy*
1215 *of Sciences of the United States of America* **109**:E260-7. doi:10.1073/pnas.1116776109

1216 Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, Shrestha K,
1217 Cahan P, Stanger BZ, Camargo FD. 2014. Hippo Pathway Activity Influences Liver Cell
1218 Fate. *Cell* **157**:1324–1338. doi:10.1016/J.CELL.2014.03.060

1219 You J, Croyle JL, Nishimura A, Ozato K, Howley PM. 2004. Interaction of the bovine
1220 papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes.
1221 *Cell* **117**:349–360. doi:10.1016/S0092-8674(04)00402-7

1222 Yuan Y, Park J, Feng A, Awasthi P, Wang Z, Chen Q, Iglesias-Bartolome R. 2020. YAP1/TAZ-
1223 TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation
1224 and limiting KLF4 activity. *Nature Communications* **11**:1–14. doi:10.1038/s41467-020-
1225 15301-0

1226 Yuan Y, Salinas Parra N, Chen Q, Iglesias-Bartolome R. 2021. Oncogenic Hedgehog-
1227 Smoothed Signaling Depends on YAP1–TAZ/TEAD Transcription to Restrain
1228 Differentiation in Basal Cell Carcinoma. *Journal of Investigative Dermatology*.
1229 doi:10.1016/J.JID.2021.06.020

1230 Yun H-Y, Kim MW, Lee HS, Kim W, Shin JH, Kim H, Shin H-C, Park H, Oh B-H, Kim WK, Bae
1231 K-H, Lee SC, Lee E-W, Ku B, Kim SJ. 2019. Structural basis for recognition of the tumor
1232 suppressor protein PTPN14 by the oncoprotein E7 of human papillomavirus. *PLOS Biology*
1233 **17**:e3000367. doi:10.1371/journal.pbio.3000367

1234 Zhang H, Pasolli HA, Fuchs E. 2011. Yes-associated protein (YAP) transcriptional coactivator
1235 functions in balancing growth and differentiation in skin. *Proceedings of the National*
1236 *Academy of Sciences* **108**:2270–2275. doi:10.1073/pnas.1019603108

1237 Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K,
1238 Chinnaiyan A, Halder G, Lai Z-C, Guan K-L. 2007. Inactivation of YAP oncoprotein by the
1239 Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes &*
1240 *Development* **21**:2747–2761. doi:10.1101/GAD.1602907

1241 Zhao R, Fallon TR, Saladi SV, Pardo-Saganta A, Villoria J, Mou H, Vinarsky V, Gonzalez-
1242 Celeiro M, Nunna N, Hariri LP, Camargo F, Ellisen LW, Rajagopal J. 2014. Yap Tunes
1243 Airway Epithelial Size and Architecture by Regulating the Identity, Maintenance, and Self-
1244 Renewal of Stem Cells. *Developmental Cell* **30**:151–165. doi:10.1016/j.devcel.2014.06.004

1245

Figure 1—figure supplement 1 | HPV-positive HNSCC have fewer Hippo pathway alterations and lower expression of differentiation genes. cBioPortal analysis for genomic mutations and copy number alterations in HPV+/- HNSCC and OPSCC. Oncoprint displays specific genomic alterations in individual tumor samples.

A

B

Figure 1—figure supplement 2 | HPV18 E7 activates YAP1 in basal keratinocytes. (A-B) Additional replicates of organotypic cultures grown from primary HFK or HFK harboring the HPV18 genome. FFPE sections were stained for YAP1 (magenta), PCNA (green), and Hoechst (gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μm. Inset scale bars = 25 μm.

A

B

C

Figure 1—figure supplement 3 | HPV E7 activates YAP1 in basal keratinocytes. Additional replicates of organotypic cultures grown from primary HFK or HFK transduced with retroviral expression encoding HPV E7 proteins. FFPE sections of cultures grown from (A) HFK or HFK expressing HPV16 E7 or HPV18 E7, (B) HFK or HFK transduced with HPV16 E7, or (E) HFK and HFK expressing HPV18 E7 were stained for YAP1 (magenta), PCNA (green), and Hoechst (gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μm. Inset scale bars = 25 μm.

Figure 1—figure supplement 4 | HPV E6 does not activate YAP1 in basal keratinocytes. Additional replicates of organotypic cultures grown from primary HFK or HFK transduced with retroviral expression encoding HPV E6 or E7 proteins. FFPE sections were stained for YAP1 (magenta), PCNA (green), and Hoechst (gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μ m. Inset scale bars = 25 μ m.

Figure 2—figure supplement 1 | PTPN14 knockout activates YAP1 in basal keratinocytes. Additional replicates of organotypic cultures grown from N/Tert-Cas9 keratinocytes (A-C) FFPE sections from mock or sgPTPN14 transfected N/Tert-Cas9 keratinocytes were stained for YAP1 (magenta), IVL (green), and Hoechst (Gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μ m. Inset scale bars = 25 μ m.

Figure 2—figure supplement 2 | HPV E7 activates YAP1 in basal keratinocytes through PTPN14 degradation. Additional replicates of organotypic cultures grown from primary HFK transduced with retroviral expression vectors encoding HPV18 E7 WT or R84S. FFPE sections from parental HFK, HPV18 E7 WT or HPV18 E7 R84S expressing HFK were stained for YAP1 (magenta), PCNA (green), and Hoechst (Gray). White dashed lines indicate the basement membrane. White boxes indicate the location of insets in main images. Main image scale bars = 100 μm. Inset scale bars = 25 μm.

Figure 3—figure supplement 1 | PTPN14 expression is enriched in basal keratinocytes in HPV 18 E7 expressing organotypic cultures. Basal and suprabasal layers from a 3D organotypic culture grown from HFK transduced with a retroviral expression vector encoding HPV18 E7 were dissected using laser capture microdissection. RNA was purified from isolated layers and qRT-PCR was used to assess the expression of PTPN14 (A), the basal cell markers ITGA6 and ITGB4 (B), and the differentiation marker IVL (C). Graphs display individual data points.

Figure 4—figure supplement 1 | PTPN14 overexpression promotes differentiation in keratinocytes.

NTert-Cas9 Mock and sgPTPN14-1 keratinocytes were transduced with lentiviruses encoding GFP or PTPN14 or the empty vector control. (A) Cell lysates were subjected to SDS/PAGE/Western analysis and probed with antibodies to PTPN14, V5-tag, Involucrin, and Actin. (B) qRT-PCR was used to measure the expression of the differentiation markers IVL and KRT10 relative to G6PD. Graphs display the mean $\pm$ SD of two independent replicates.

Figure 4—figure supplement 2 | YAP1 and TAZ are required for PTPN14 to promote keratinocyte differentiation. Primary HFK were transfected with control or YAP1 and WWTR1 targeting siRNAs then transduced with PTPN14 encoding lentivirus. qRT-PCR was used to measure the expression of the differentiation markers (A) KRT1 and (B) IVL relative to G6PD. Graphs portray the change in gene expression relative to siC. Graphs display the mean $\pm$ SD of three independent replicates. Statistical significance was determined by ANOVA (** $p < 0.01$, *** $p < 0.001$).

Figure 5—figure supplement 1 | HPV-positive HNSCC express lower levels of differentiation genes. RNA-seq data from TCGA were accessed through cBioPortal. Violin plots display the distribution in log₂ mRNA expression of differentiation markers (A) KRT1, (B) KRT10, and (C) IVL, and the canonical YAP1/TAZ targets (D) CTGF and (E) CYR61. Statistical significance was determined by Mann-Whitney nonparametric test. (**p<0.01, ***p<0.001, ****p<0.0001).

Figure 7—figure supplement 1 | PTPN14 degradation by HPV E7 promotes basal cell retention. (A-B) GFP-labeled HFK were transduced with YAP1 WT, YAP1 S127A, or YAP1 S94A under the control of a doxycycline inducible promoter. (A) GFP expression was confirmed by fluorescence microscopy. Scale bar = 100 μ m. (B) Total RNA was purified from monolayer cells +/- treatment with 1 μ g/mL doxycycline for 72h. qRT-PCR was used to assess gene expression of YAP1 and CTGF. (C-D) GFP-labeled HFK were transduced with retroviral vectors encoding HPV18 WT, HPV18 Δ DLCC, HPV18 E7 R84S, or the empty vector control (EV). (C) GFP expression was confirmed by fluorescence microscopy. Scale bar = 100 μ m. (D) Cell lysates were subjected to SDS/PAGE/Western analysis and probed with antibodies to PTPN14, RB1, and Actin. (E-F) GFP-labeled HFK were transduced with LentiCRISPR v2 sgNT-1, sgPTPN14-3, or sgPTPN14-4 vectors. (E) GFP expression was confirmed by fluorescence microscopy. Scale bar = 100 μ m (F) Cell lysates were subjected to SDS/PAGE/Western analysis and probed with antibodies to PTPN14 and Actin.

Figure 7—figure supplement 2 | HPV18 E7 can promote basal cell retention in the absence of RB1 binding. Organotypic cultures were grown from GFP-labeled cells mixed with unmodified HFK. GFP-labeled HFK were transduced with HPV18 E7 Δ DLLC or the empty vector (EV). GFP-labeled cells were mixed 1:50 into unmodified HFK. (A) FFPE sections were stained for GFP (green), IVL (grey), and Hoechst (blue). Scale bar = 100 μ m (B) Quantification of the percentage of GFP+ cells found in the basal layer. Graphs display the mean $\pm$ SD and each individual data point (independent cultures). Statistical significance was determined by t-test. (** $p < 0.01$).

Key Resources Table

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
antibody	anti-Actin (Mouse monoclonal)	Sigma-Aldrich	Cat#: MAB1501	WB (1:20,000)
antibody	anti-GFP (Rabbit polyclonal)	Invitrogen	Cat#: A6455	WB (1:1,000); IHC-P (1:2000)
antibody	anti-Mouse IgG Alexa Fluor 488 (Goat polyclonal)	Invitrogen	Cat#: A11001	IHC-P (1:250)
antibody	anti-Mouse IgG HRP (Horse monoclonal)	Cell Signaling Technologies	Cat#: 7076	WB (1:2000)
antibody	anti-Rabbit IgG Alexa Fluor 594 (Goat polyclonal)	Invitrogen	Cat#: A11012	IHC-P (1:250)
antibody	anti-Rabbit IgG HRP (Goat monoclonal)	Cell Signaling Technologies	Cat#: 7074	WB (1:2000)
antibody	anti-HA-Peroxidase (Rat monoclonal)	Roche	Cat#: 12013819001	WB (1:500)
antibody	anti-ITGB4 (Rabbit polyclonal)	Sigma-Aldrich	Cat#: HPA036348	IHC-P (1:100)
antibody	anti-IVL (Mouse monoclonal)	Santa Cruz Biotechnology	Cat#: sc-398952	IHC-P (1:100)
antibody	anti-KRT1 (Mouse monoclonal)	Enzo Life Sciences	Cat#: C34904	
antibody	anti-PCNA	Santa Cruz Biotechnology	Cat#: sc-56	IHC-P (1:100)

antibody	Anti-PTPN14 (Rabbit monoclonal)	Cell Signaling Technology	D5T6Y; Cat#: 13808	WB (1:500)
antibody	anti-TAZ (Rabbit monoclonal)	Cell Signaling Technology	D3I6D; Cat#: 70148	WB (1:1000)
antibody	anti-V5 (Mouse monoclonal)	Invitrogen	Cat#: 46-0705	WB (1:1000)
antibody	anti-YAP1 (Rabbit monoclonal)	Cell Signaling Technology	D8H1X; Cat#: 14074	WB (1:1000); IHC-P (1:50)
transfected construct (human)	nontargeting siRNA	Dharmacon	Cat#: D-001810-01	
transfected construct (human)	siRNA to YAP1 (OnTarget Plus)	Dharmacon	Cat#: J-012200-06	
transfected construct (human)	siRNA to YAP1 (OnTarget Plus)	Dharmacon	Cat#: J-012200-08	
transfected construct (human)	siRNA to WWTR1 (OnTarget Plus)	Dharmacon	Cat#: J-016083-06	
transfected construct (human)	siRNA to WWTR1 (OnTarget Plus)	Dharmacon	Cat#: J-016083-08	
transfected construct (human)	siRNA to PTPN14 (OnTarget Plus)	Dharmacon	Cat#: J-008509-05	
transfected construct (human)	siRNA to PTPN14 (OnTarget Plus)	Dharmacon	Cat#: J-008509-08	
transfected construct (human)	siRNA to LATS1 (OnTarget Plus)	Dharmacon	Cat#: J-004632-05	
transfected construct (human)	siRNA to LATS1 (OnTarget Plus)	Dharmacon	Cat#: J-004632-08	

transfected construct (human)	siRNA to LATS2 (OnTarget Plus)	Dharmacon	Cat#: J-003865-09	
transfected construct (human)	siRNA to LATS2 (OnTarget Plus)	Dharmacon	Cat#: J-003865-10	

Supplemental File 1
Plasmids used in the study

White lab									
Plasmid #	Plasmid name	Gene	Promoter	Bacterial Resistance	Tag	Tag location	Selectable Marker	Addgene Number	Original Source
8130	MSCV/ GFP C-FlagHA	GFP	MSCV LTR	Ampicillin	Flag, HA	C terminus	Puromycin	n/a	This Study
6640	MSCV/P C-FlagHA 18E7	HPV16 E7	MSCV LTR	Ampicillin	Flag, HA	C terminus	Puromycin	35018	White et al. (2012) PNAS: 109(5):E280–E287
6641	MSCV/P C-FlagHA 18E7	HPV18 E7	MSCV LTR	Ampicillin	Flag, HA	C terminus	Puromycin	35019	White et al. (2012) PNAS: 109(5):E280–E287
8193	MSCV/P C-FlagHA 18E7/ R84S	HPV18 E7	MSCV LTR	Ampicillin	Flag, HA	C terminus	Puromycin	163307	Hatterschilde et al. (2020) J. Virol. 94:e1024-20
6659	MSCV/P N-FlagHA 16E6	HPV16 E6	MSCV LTR	Ampicillin	Flag, HA	C terminus	Puromycin	44152	White et al. (2012) J. Virol. 86(24):13174-86
8208	MSCV/Neo C-HA Empty	Empty	MSCV LTR	Ampicillin	HA	C terminus	Neomycin	163310	Hatterschilde et al. (2020) J. Virol. 94:e1024-20
8133	MSCV/ GFP Neo C-HA	GFP	MSCV LTR	Ampicillin	HA	C terminus	Neomycin	n/a	This Study
6993	MSCV/Neo C-HA 18E7	HPV18 E7	MSCV LTR	Ampicillin	HA	C terminus	Neomycin	163311	Hatterschilde et al. (2020) J. Virol. 94:e1024-20
8220	MSCV/Neo C-HA 18E7 R84S	HPV18 E7	MSCV LTR	Ampicillin	HA	C terminus	Neomycin	163312	Hatterschilde et al. (2020) J. Virol. 94:e1024-20
8291	MSCV/Neo C-HA 18E7 ADLLC	HPV18 E7	MSCV LTR	Ampicillin	HA	C terminus	Neomycin	n/a	This Study
8340	Plenti CMV GFP Hygro (95e-4)	GFP	CMV	Ampicillin	n/a	C terminus	Hygromycin	17746	Campeau et al. (2009) PLoS One. 4(8):e6529
6571	PHAGE-P-CMV NHA GFP	GFP	PTPN14	Ampicillin	HA	N terminus	Puromycin	n/a	Galligan et al. (2015) J Proteome Res. 14(2): 953-966
7322	PHAGE-P N-V5 PTPN14	PTPN14	CMV	Ampicillin	V5	N terminus	Puromycin	n/a	White et al. (2016) mBio. 7(5):e01530-16
8251	POCXI/Myc-YAP	YAP1 isoform 3	CMV	Ampicillin	Myc	C terminus	Hygromycin	33091	Zhao et al. (2007) Genes Dev. 21(21):2747-61
8252	POCXI/Flag-YAP S127A	YAP1 isoform 3	CMV	Ampicillin	Flag	C terminus	Hygromycin	33092	Zhao et al. (2007) Genes Dev. 21(21):2747-61
8254	POCXI/Myc-YAP S94A	YAP1 isoform 3	CMV	Ampicillin	Myc	C terminus	Hygromycin	33094	Zhao et al. (2007) Genes Dev. 21(21):2747-61
8319	PDONR ATG-YAP1 WT-Stop	YAP1 isoform 3	n/a	Spectinomycin	n/a	n/a	n/a	n/a	This Study
8321	PDONR ATG-YAP1 S127A-Stop	YAP1 isoform 3	n/a	Spectinomycin	n/a	n/a	n/a	n/a	This Study
8322	PDONR ATG-YAP1 S94A-Stop	YAP1 isoform 3	TRE promoter, Tet ON	Ampicillin	n/a	n/a	Puromycin	n/a	This Study
8325	PLUX YAP1 WT	YAP1 isoform 3	TRE promoter, Tet ON	Ampicillin	n/a	n/a	Puromycin	n/a	This Study
8327	PLUX YAP1 S127A	YAP1 isoform 3	TRE promoter, Tet ON	Ampicillin	n/a	n/a	Puromycin	n/a	This Study
8328	PLUX YAP1 S94A	YAP1 isoform 3	TRE promoter, Tet ON	Ampicillin	n/a	n/a	Puromycin	n/a	This Study
8278	plindoe20 EGFP-TEADl	EGFP-TEADl	TRE promoter, Tet ON	Ampicillin	GFP	C terminus	Neomycin	140145	Yuan et al. (2020) Nat Commun. 11, 1472
White lab									
Plasmid #	Plasmid name	HPV genome	Bacterial Resistance	Selectable Marker	Original source				
8216	pNeo-loxP-HPV18	HPV18	Kanamycin	Neomycin	Wang et al. (2009) Genes Dev. 23:181-94.				
White lab									
Plasmid #	Plasmid name	sgRNA sequence from Broad	Promoter	Bacterial Resistance	Selectable Marker	Addgene Number	Original Source		
8092	LentiCRISPR v2 sgNT-1	AGCTCGCAGTGTGGTTCTC	U6	Ampicillin	Puromycin	163315	Hatterschilde et al. (2020) J. Virol. 94:e1024-20		
8115	LentiCRISPR v2 sgPTPN14-3	CCACACTGGACGTGAACGGG	U6	Ampicillin	Puromycin	163314	Hatterschilde et al. (2019) PNAS: 116:7033-7042		
8116	LentiCRISPR v2 sgPTPN14-4	TGTGCTTACCGTGTGAAGA	U6	Ampicillin	Puromycin	163316	Hatterschilde et al. (2020) J. Virol. 94:e1024-20		

Supplemental File 1
Antibodies used in the study

Target	Antibody Name	Company	Product Number	Use	Dilution	Notes
Actin	Anti-Actin Antibody, clone C4	Sigma-Aldrich	MAB1501	Western Blot	1:20000	HIER: 10 mM Sodium Citrate pH 6
GFP	GFP Polyclonal Antibody	Invitrogen	A6455	IHC-P	1:2000	
GFP	GFP Polyclonal Antibody	Invitrogen	A6455	Western Blot	1:1000	
Goat anti-Mouse IgG 488	Goat anti-Mouse IgG (H+L) Alexa Fluor 488	Invitrogen	A11001	IHC-P	1:250	
Goat anti-mouse IgG HRP	Anti-mouse IgG, HRP-linked Antibody	Cell Signaling Technology	7076	Western Blot	1:2000	HIER: 10 mM Sodium Citrate pH 6 or Tris-EDTA pH 10
Goat anti-Rabbit IgG 594	Goat anti-Rabbit IgG (H+L) Alexa Fluor 594	Invitrogen	A11012	IHC-P	1:250	
Goat anti-Rabbit IgG HRP	Anti-Rabbit IgG, HRP-linked Antibody	Cell Signaling Technology	7074	Western Blot	1:2000	
HA	Anti-HA-Peroxidase	Roche	12013819001	Western Blot	1:500	
ITGB4	Anti-ITGB4 antibody	Sigma-Aldrich	HPA036348	IHC-P	1:100	HIER: Tris-EDTA pH 10
IVL	Anti-Involucrin Antibody (A-5)	Santa Cruz Biotechnology	sc-398952	IHC-P	1:100	HIER: either 10 mM Sodium Citrate pH 6 or Tris-EDTA pH 10
KRT1	Cytokeratin 1 (human) monoclonal antibody (348B4)	Enzo Life Sciences	C34904	IHC-P (TMA)	-	HIER: Tris-EDTA pH 10
PCNA	Anti-PCNA Antibody (PC-10)	Santa Cruz Biotechnology	sc-56	IHC-P	1:100	
PTPN14	PTPN14 (D5T6Y)	Cell Signaling Technology	13808	Western Blot	1:500	
TAZ	TAZ (D3I6D)	Cell Signaling Technology	70148	Western Blot	1:1000	
V5	Anti-V5 Tag Antibody	Invitrogen	46-0705	Western Blot	1:1000	HIER: Tris-EDTA pH 10
YAP1	YAP (D8H1X) XP	Cell Signaling Technology	14074	IHC-P	1:50	
YAP1	YAP (D8H1X) XP	Cell Signaling Technology	14074	Western Blot	1:1000	

Homogenous HFK Organotypic Cultures
Raft Condition White Lab IC

Protein	Accession	Gene	Accession
HRK-1	0607201033.HRK	None	4659
HRK-2	0609211130.HRK1	None	4659
HRK-3	0609211130.HRK2	None	4659
HPv18 LoP-1	012720201431.WT1	phc-hoP-HPv18	4659
HPv18 LoP-2	012720201431.WT2	phc-hoP-HPv18	4659
HPv18 ET WT-1	040520211003.18EWT1	MSOv/P C-Floppia 18E7	4659
HPv18 ET WT-2	040520211003.18EWT2	MSOv/P C-Floppia 18E7	4659
HPv18 ET WT-1	072220201051.18EWT1	MSOv/P C-Floppia 18E7	4659
HPv18 ET WT-2	072220201051.18EWT2	MSOv/P C-Floppia 18E7	4659
HPv18 ET WT-3	080720201032.18EWT1	MSOv/P C-Floppia 18E7	4659
HPv18 ET WT-4	080720201032.18EWT2	MSOv/P C-Floppia 18E7	4659
HPv18 ET WT-5	080720201051.18EWT3	MSOv/P C-Floppia 18E7	4659
HPv18 ET RMs-1	072220201031.18E7.RMs1	MSOv/P C-Floppia 18E7 RMs	4659
HPv18 ET RMs-3	080720201032.18E7.RMs3	MSOv/P C-Floppia 18E7 RMs	4659
HPv18 ET RMs-4	080720201033.18E7.RMs2	MSOv/P C-Floppia 18E7 RMs	4659
HPv18 E6-1	040520211003.18E6-2	MSOv/P N-Floppia 18E6	4659
HPv18 E6-2	040520211003.18E6-3	MSOv/P N-Floppia 18E6	4659

Homogenous N/Tert-Cas9 Organotypic Cultures

[illegible]

Cell Fate Organotypic Cultures

IRF1		IRF2		IRF3		IRF4		IRF5		IRF6		IRF7		IRF8		IRF9		IRF10		IRF11		IRF12		IRF13		IRF14		IRF15		IRF16		IRF17		IRF18		IRF19		IRF20		IRF21		IRF22		IRF23		IRF24		IRF25		IRF26		IRF27		IRF28		IRF29		IRF30		IRF31		IRF32		IRF33		IRF34		IRF35		IRF36		IRF37		IRF38		IRF39		IRF40		IRF41		IRF42		IRF43		IRF44		IRF45		IRF46		IRF47		IRF48		IRF49		IRF50		IRF51		IRF52		IRF53		IRF54		IRF55		IRF56		IRF57		IRF58		IRF59		IRF60		IRF61		IRF62		IRF63		IRF64		IRF65		IRF66		IRF67		IRF68		IRF69		IRF70		IRF71		IRF72		IRF73		IRF74		IRF75		IRF76		IRF77		IRF78		IRF79		IRF80		IRF81		IRF82		IRF83		IRF84		IRF85		IRF86		IRF87		IRF88		IRF89		IRF90		IRF91		IRF92		IRF93		IRF94		IRF95		IRF96		IRF97		IRF98		IRF99		IRF100		IRF101		IRF102		IRF103		IRF104		IRF105		IRF106		IRF107		IRF108		IRF109		IRF110		IRF111		IRF112		IRF113		IRF114		IRF115		IRF116		IRF117		IRF118		IRF119		IRF120		IRF121		IRF122		IRF123		IRF124		IRF125		IRF126		IRF127		IRF128		IRF129		IRF130		IRF131		IRF132		IRF133		IRF134		IRF135		IRF136		IRF137		IRF138		IRF139		IRF140		IRF141		IRF142		IRF143		IRF144		IRF145		IRF146		IRF147		IRF148		IRF149		IRF150		IRF151		IRF152		IRF153		IRF154		IRF155		IRF156		IRF157		IRF158		IRF159		IRF160		IRF161		IRF162		IRF163		IRF164		IRF165		IRF166		IRF167		IRF168		IRF169		IRF170		IRF171		IRF172		IRF173		IRF174		IRF175		IRF176		IRF177		IRF178		IRF179		IRF180		IRF181		IRF182		IRF183		IRF184		IRF185		IRF186		IRF187		IRF188		IRF189		IRF190		IRF191		IRF192		IRF193		IRF194		IRF195		IRF196		IRF197		IRF198		IRF199		IRF200		IRF201		IRF202		IRF203		IRF204		IRF205		IRF206		IRF207		IRF208		IRF209		IRF210		IRF211		IRF212		IRF213		IRF214		IRF215		IRF216		IRF217		IRF218		IRF219		IRF220		IRF221		IRF222		IRF223		IRF224		IRF225		IRF226		IRF227		IRF228		IRF229		IRF230		IRF231		IRF232		IRF233		IRF234		IRF235		IRF236		IRF237		IRF238		IRF239		IRF240		IRF241		IRF242		IRF243		IRF244		IRF245		IRF246		IRF247		IRF248		IRF249		IRF250		IRF251		IRF252		IRF253		IRF254		IRF255		IRF256		IRF257		IRF258		IRF259		IRF260		IRF261		IRF262		IRF263		IRF264		IRF265		IRF266		IRF267		IRF268		IRF269		IRF270		IRF271		IRF272		IRF273		IRF274		IRF275		IRF276		IRF277		IRF278		IRF279		IRF280		IRF281		IRF282		IRF283		IRF284		IRF285		IRF286		IRF287		IRF288		IRF289		IRF290		IRF291		IRF292		IRF293		IRF294		IRF295		IRF296		IRF297		IRF298		IRF299		IRF300		IRF301		IRF302		IRF303		IRF304		IRF305		IRF306		IRF307		IRF308		IRF309		IRF310		IRF311		IRF312		IRF313		IRF314		IRF315		IRF316		IRF317		IRF318		IRF319		IRF320		IRF321		IRF322		IRF323		IRF324		IRF325		IRF326		IRF327		IRF328		IRF329		IRF330		IRF331		IRF332		IRF333		IRF334		IRF335		IRF336		IRF337		IRF338		IRF339		IRF340		IRF341		IRF342		IRF343		IRF344		IRF345		IRF346		IRF347		IRF348		IRF349		IRF350		IRF351		IRF352		IRF353		IRF354		IRF355		IRF356		IRF357		IRF358		IRF359		IRF360		IRF361		IRF362		IRF363		IRF364		IRF365		IRF366		IRF367		IRF368		IRF369		IRF370		IRF371		IRF372		IRF373		IRF374		IRF375		IRF376		IRF377		IRF378		IRF379		IRF380		IRF381		IRF382		IRF383		IRF384		IRF385		IRF386		IRF387		IRF388		IRF389		IRF390		IRF391		IRF392		IRF393		IRF394		IRF395		IRF396		IRF397		IRF398		IRF399		IRF400		IRF401		IRF402		IRF403		IRF404		IRF405		IRF406		IRF407		IRF408		IRF409		IRF410		IRF411		IRF412		IRF413		IRF414		IRF415		IRF416		IRF417		IRF418		IRF419		IRF420		IRF421		IRF422		IRF423		IRF424		IRF425		IRF426		IRF427		IRF428		IRF429		IRF430		IRF431		IRF432		IRF433		IRF434		IRF435		IRF436		IRF437		IRF438		IRF439		IRF440		IRF441		IRF442		IRF443		IRF444		IRF445		IRF446		IRF447		IRF448		IRF449		IRF450		IRF451		IRF452		IRF453		IRF454		IRF455		IRF456		IRF457		IRF458		IRF459		IRF460		IRF461		IRF462		IRF463		IRF464		IRF465		IRF466		IRF467		IRF468		IRF469		IRF470		IRF471		IRF472		IRF473		IRF474		IRF475		IRF476		IRF477		IRF478		IRF479		IRF480		IRF481		IRF482		IRF483		IRF484		IRF485		IRF486		IRF487		IRF488		IRF489		IRF490		IRF491		IRF492		IRF493		IRF494		IRF495		IRF496		IRF497		IRF498		IRF499		IRF500		IRF501		IRF502		IRF503		IRF504		IRF505		IRF506		IRF507		IRF508		IRF509		IRF510		IRF511		IRF512		IRF513		IRF514		IRF515		IRF516		IRF517		IRF518		IRF519		IRF520		IRF521		IRF522		IRF523		IRF524		IRF525		IRF526		IRF527		IRF528		IRF529		IRF530		IRF531		IRF532		IRF533		IRF534		IRF535		IRF536		IRF537		IRF538		IRF539		IRF540		IRF541		IRF542		IRF543		IRF544		IRF545		IRF546		IRF547		IRF548		IRF549		IRF550		IRF551		IRF552		IRF553		IRF554		IRF555		IRF556		IRF557		IRF558		IRF559		IRF560		IRF561		IRF562		IRF563		IRF564		IRF565		IRF566		IRF567		IRF568		IRF569		IRF570		IRF571		IRF572		IRF573		IRF574		IRF575		IRF576		IRF577		IRF578		IRF579		IRF580		IRF581		IRF582		IRF583		IRF584		IRF585		IRF586		IRF587		IRF588		IRF589		IRF590		IRF591		IRF592		IRF593		IRF594		IRF595		IRF596		IRF597		IRF598		IRF599		IRF600		IRF601		IRF602		IRF603		IRF604		IRF605		IRF606		IRF607		IRF608		IRF609		IRF610		IRF611		IRF612		IRF613		IRF614		IRF615		IRF616		IRF617		IRF618		IRF619		IRF620		IRF621		IRF622		IRF623		IRF624		IRF625		IRF626		IRF627		IRF628		IRF629		IRF630		IRF631		IRF632		IRF633		IRF634		IRF635		IRF636		IRF637		IRF638		IRF639		IRF640		IRF641		IRF642		IRF643		IRF644		IRF645		IRF646		IRF647		IRF648		IRF649		IRF650		IRF651		IRF652		IRF653		IRF654		IRF655		IRF656		IRF657		IRF658		IRF659		IRF660		IRF661		IRF662		IRF663		IRF664		IRF665		IRF666		IRF667		IRF668		IRF669		IRF670		IRF671		IRF672		IRF673		IRF674		IRF675		IRF676		IRF677		IRF678		IRF679		IRF680		IRF681		IRF682		IRF683		IRF684		IRF685		IRF686		IRF687		IRF688		IRF689		IRF690		IRF691		IRF692		IRF693		IRF694		IRF695		IRF696		IRF697		IRF698		IRF699		IRF700		IRF701		IRF702		IRF703		IRF704		IRF705		IRF706		IRF707		IRF708		IRF709		IRF710		IRF711		IRF712		IRF713		IRF714		IRF715		IRF716		IRF717		IRF718		IRF719		IRF720		IRF721		IRF722		IRF723		IRF724		IRF725		IRF726		IRF727		IRF728		IRF729		IRF730		IRF731		IRF732		IRF733		IRF734		IRF735		IRF736		IRF737		IRF738		IRF739		IRF740		IRF741		IRF742		IRF743		IRF744		IRF745		IRF746		IRF747		IRF748		IRF749		IRF750		IRF751		IRF752		IRF753		IRF754		IRF755		IRF756		IRF757		IRF758		IRF759		IRF760		IRF761		IRF762		IRF763		IRF764		IRF765		IRF766		IRF767		IRF768		IRF769		IRF770		IRF771		IRF772		IRF773		IRF774		IRF775		IRF776		IRF777		IRF778		IRF779		IRF780		IRF781		IRF782		IRF783		IRF784		IRF785		IRF786		IRF787		IRF788		IRF789		IRF790		IRF791		IRF792		IRF793		IRF794		IRF795		IRF796		IRF797		IRF798		IRF799		IRF800		IRF801		IRF802		IRF803		IRF804		IRF805		IRF806		IRF807		IRF808		IRF809		IRF810		IRF811		IRF812		IRF813		IRF814		IRF815		IRF816		IRF817		IRF818		IRF819		IRF820		IRF821		IRF822		IRF823		IRF824		IRF825		IRF826		IRF827		IRF828		IRF829		IRF830		IRF831		IRF832		IRF833		IRF834		IRF835		IRF836		IRF837		IRF838		IRF839		IRF840		IRF841		IRF842		IRF843		IRF844		IRF845		IRF846		IRF847		IRF848		IRF849		IRF850		IRF851		IRF852		IRF853		IRF854		IRF855		IRF856		IRF857		IRF858		IRF859		IRF860		IRF861		IRF862		IRF863		IRF864		IRF865		IRF866		IRF867		IRF868		IRF869		IRF870		IRF871		IRF872		IRF873		IRF874		IRF875		IRF876		IRF877		IRF878		IRF879		IRF880		IRF881		IRF882		IRF883		IRF884		IRF885		IRF886		IRF887		IRF888		IRF889		IRF890		IRF891		IRF892		IRF893		IRF894		IRF895		IRF896		IRF897		IRF898		IRF899		IRF900		IRF901		IRF902		IRF903		IRF904		IRF905		IRF906		IRF907		IRF908		IRF909		IRF910		IRF911		IRF912		IRF913		IRF914		IRF915		IRF916		IRF917		IRF918		IRF919		IRF920		IRF921		IRF922		IRF923		IRF924		IRF925		IRF926		IRF927		IRF928		IRF929		IRF930		IRF931		IRF932		IRF933		IRF934		IRF935		IRF936		IRF937		IRF938		IRF939		IRF940		IRF941		IRF942		IRF943		IRF944		IRF945		IRF946		IRF947		IRF948		IRF949		IRF950		IRF951		IRF952		IRF953		IRF954		IRF955		IRF956		IRF957		IRF958		IRF959		IRF960		IRF9	
------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	-------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	------	--

List of Figures *inclusion of a single culture in >1 figure indicates that separate sections of the culture were processed independently

[illegible]

List of Figures *Inclusion of a single culture in >1 figure indicates that separate sections of the culture were processed independently

Figure 2-figure supplement 1C
Figure 2-figure supplement 1B
Figure 2-figure supplement 1A
Figure 2-figure supplement 1B
Figure 2B

Dilution (Tracer:Unmodified)	List of Figures
1:1	Fig. 1
1:2	Fig. 2
1:4	Fig. 3
1:8	Fig. 4
1:16	Fig. 5
1:32	Fig. 6
1:64	Fig. 7
1:128	Fig. 8
1:256	Fig. 9
1:512	Fig. 10
1:1024	Fig. 11
1:2048	Fig. 12
1:4096	Fig. 13
1:8192	Fig. 14
1:16384	Fig. 15
1:32768	Fig. 16
1:65536	Fig. 17
1:131072	Fig. 18
1:262144	Fig. 19
1:524288	Fig. 20
1:1048576	Fig. 21
1:2097152	Fig. 22
1:4194304	Fig. 23
1:8388608	Fig. 24
1:16777216	Fig. 25
1:33554432	Fig. 26
1:67108864	Fig. 27
1:134217728	Fig. 28
1:268435456	Fig. 29
1:536870912	Fig. 30
1:1073741824	Fig. 31
1:2147483648	Fig. 32
1:4294967296	Fig. 33
1:8589934592	Fig. 34
1:17179869184	Fig. 35
1:34359738368	Fig. 36
1:68719476736	Fig. 37
1:137438953472	Fig. 38
1:274877906944	Fig. 39
1:549755813888	Fig. 40
1:1099511627776	Fig. 41
1:2199023255552	Fig. 42
1:4398046511104	Fig. 43
1:8796093022208	Fig. 44
1:17592186044416	Fig. 45
1:35184372088832	Fig. 46
1:70368744177664	Fig. 47
1:140737488355328	Fig. 48
1:281474976710656	Fig. 49
1:562949953421312	Fig. 50
1:1125899906842624	Fig. 51
1:2251799813685248	Fig. 52
1:4503599627370496	Fig. 53
1:9007199254740992	Fig. 54
1:18014398509481984	Fig. 55
1:36028797018963968	Fig. 56
1:72057594037927936	Fig. 57
1:144115188075855872	Fig. 58
1:288230376151711744	Fig. 59
1:576460752303423488	Fig. 60
1:1152921504606846976	Fig. 61
1:2305843009213693952	Fig. 62
1:4611686018427387904	Fig. 63
1:9223372036854775808	Fig. 64
1:18446744073709551616	Fig. 65
1:36893488147419103232	Fig. 66
1:73786976294838206464	Fig. 67
1:147573952589676412928	Fig. 68
1:295147905179352825856	Fig. 69
1:590295810358705651712	Fig. 70
1:1180591620717411303424	Fig. 71
1:2361183241434822606848	Fig. 72
1:4722366482869645213696	Fig. 73
1:9444732965739290427392	Fig. 74
1:18889465931478580854784	Fig. 75
1:37778931862957161709568	Fig. 76
1:75557863725914323419136	Fig. 77
1:151115727451828646838272	Fig. 78
1:302231454903657293676544	Fig. 79
1:604462909807314587353088	Fig. 80
1:1208925819614629174706176	Fig. 81
1:2417851639229258349412352	Fig. 82
1:4835703278458516698824704	Fig. 83
1:9671406556917033397649408	Fig. 84
1:19342813113834066795298816	Fig. 85
1:38685626227668133590597632	Fig. 86
1:77371252455336267181195264	Fig. 87
1:154742504910672534362390528	Fig. 88
1:309485009821345068724781056	Fig. 89
1:618970019642690137449562112	Fig. 90
1:1237940039285380274899124224	Fig. 91
1:2475880078570760549798248448	Fig. 92
1:4951760157141521099596496896	Fig. 93
1:9903520314283042199192993792	Fig. 94
1:19807040628566084398385987584	Fig. 95
1:39614081257132168796771975168	Fig. 96
1:79228162514264337593543950336	Fig. 97
1:158456325028528675187087900672	Fig. 98
1:3169126500570573503741758	

[illegible]

Supplemental File 3

Tumor microarray specimen information

	Oral Cavity	Oropharynx	Total	HPV-positive	HPV-negative*
# Patients	72	48	120	33	87
Primary tumor (T-stage) †					
Early (T1 or T2)	60	40	100	27	73
Advanced (T3 or T4)	12	8	20	6	14
Nodal metastasis					
Positive	24	39	63	29	34
Negative	48	9	57	4	53
Overall pathologic stage †					
Early (I or II)	43	7	50	3	47
Advanced (III or IV)	29	41	70	30	40

*HPV status was defined by IHC for p16 for oropharyngeal tumors during routine clinical and was inferred as negative for oral cavity tumors per standards of the College of American Pathologists (Lewis et al. (2018) Archives of Pathology & Laboratory Medicine 142:559–597).

† 7th edition AJCC staging manual

Supplemental File 4

Gene Lists for Pathway Mutational Analyses

HIPPO Pathway

STK4
STK3
SAV1
LATS1
LATS2
MOB1A
MOB1B
YAP1
WWTR1
TEAD1
TEAD2
TEAD3
TEAD4
PTPN14
NF2
WWC1
TAOK1
TAOK2
TAOK3
CRB1
CRB2
CRB3
LLGL1
LLGL2
HMCN1
SCRIB
HIPK2
FAT1
FAT2
FAT3
FAT4
DCHS1
DCHS2
CSNK1E
CSNK1D
AJUBA
LIMD1
WTIP

Cell Cycle

CDKN1A
CDKN1B
CDKN2A
CDKN2B
CDKN2C
CCND1
CCND2
CCND3
CCNE1
CDK2
CDK4
CDK6
RB1
E2F1
E2F3

p53

TP53
MDM2
MDM4
ATM
CHEK2
RPS6KA3